WO1992001813A1 - Circular extension for generating multiple nucleic acid complements - Google Patents

Circular extension for generating multiple nucleic acid complements Download PDF

Info

Publication number
WO1992001813A1
WO1992001813A1 PCT/US1991/005067 US9105067W WO9201813A1 WO 1992001813 A1 WO1992001813 A1 WO 1992001813A1 US 9105067 W US9105067 W US 9105067W WO 9201813 A1 WO9201813 A1 WO 9201813A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
single strand
template
circular
linear
Prior art date
Application number
PCT/US1991/005067
Other languages
French (fr)
Inventor
Jerry L Ruth
David A. Driver
Original Assignee
Syngene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngene, Inc. filed Critical Syngene, Inc.
Priority to AU84173/91A priority Critical patent/AU649066B2/en
Priority to CA002087256A priority patent/CA2087256A1/en
Publication of WO1992001813A1 publication Critical patent/WO1992001813A1/en
Priority to NO930235A priority patent/NO930235D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions

Definitions

  • This invention relates generally to the generation of multiple complementary copies of a nucleic acid and, more particularly, to the generation of such complementary copies using novel circular templates.
  • PCR polymerase chain reaction
  • PCR is based on the enzymatic amplification of a DNA sequence that is flanked by two oligonucleotide primers which hybridize to opposite strands of the target sequence.
  • the primers are oriented with their 3' ends pointing towards each other. Repeated cycles of heat denaturation of the template, annealing of the primers to their complementary sequences and extension of the annealed primers with a DNA polymerase result in the amplification of the segment defined by the 5' ends of the PCR primers. Since the extension product of each primer can serve as a template for the other primer, each cycle results in the exponential accu-nu tion of the specific target fragment, up to several mill unfold in a few hours.
  • the method can be used with a complex template such as genomic DNA and can amplify a single-copy gene contained therein. It is also capable of amplifying a single molecule of target DNA in a
  • RNAs or DNAs can, under some conditions, produce fragments up to ten kbp long.
  • the PCR technology is the subject matter of United States Patent Nos. 4,683,195, 4,800,159, 4,754,065, and 4,683,202 all of which are incorporated herein by reference.
  • LCR The ligation chain reaction
  • probes a ligase enzyme to join preformed stretches of DNA. Once these probes find their complementary target sequences and anneal to them, the ligase joins the target sequences together, setting up a situation analogous to that found in PCR: two templates are formed, both of which can serve in the next cycle to generate more copies of the target sequence.
  • Q ⁇ replicase is another alternative for exponentially amplifying a target sequence. This method relies on the ability of the enzyme Q ⁇ replicase to generate copies of recombinant RNA molecules.
  • Q ⁇ replicase is an RNA-directed tRNA polymerase of bacteriophage Q ⁇ . The sequence to be amplified is cloned into a gene coding for a natural template of Q ⁇ , such as MDV-1 RNA, and produced as a recombinant RNA. For target amplification, the recombinant RNAs hybridize to complementary DNA and serve as templates for RNA synthesis. See Kramer and Lazardi, Nature 339:401- 402 (1989) , which is incorporated herein by reference.
  • TAS Transcription-based amplification
  • the invention provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site.
  • the process includes combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; and extending the polynucleotide primer more than once around the circle to generate a complementary displacement of more than one contiguous complement of the single strand, circular nucleic acid template.
  • the invention further provides a process of synthesizing novel single strand, circular nucleic acids between 30 and 2200 nucleotides, by synthesizing a linear polynucleotide and ligating the linear polynucleotide to produce a single strand, circular nucleic acid. 5
  • FIGURE 1 is a schematic diagram of a single-stranded circle.
  • A represents a target sequence, ""--1000 bases in length, complementary to the polynucleoti--. primer; B and C represent sequences, 0-400 bases in length, which are used as detection sequences for circle complement; d-f represent linking sequences of 0-100 bases in length. Any of A-e may contain one or more restriction sites.
  • FIGURE 2 is a schematic diagram for generating multiple nucleic acid complements.
  • G represents single- stranded circle primed for extension by a target polynucleotide; H represents excess single-stranded circle; I represents G extended by polymerizing enzymes after displacement to form multiple linear concatemers; J represents I cleaved into smaller fragments; K represents H primed by fragments from J; Reaction 1 is extension of primer by polymerizing enzymes; Reaction 2 is cleavage of I to form J; Reaction 3 is reannealing of fragments from J to circles H.
  • FIGURE 3 is a schematic diagram of constructs for making single-stranded circles.
  • L represents one linear fragment circularized by linker m before ligation;
  • N represents formation of a circle composed of two or -more fragments o and p, each 15-1100 bases in length which may be similar or different in sequence;
  • Q represents formation of a circle capable of forming at least one stem structure by ligation of two subunits containing loops r and s;
  • T represents formation of a circle capable of forming at least one stem structure by ligation of a single linear fragment containing loops r and s;
  • U represents formation of a circle capable of forming one or more stem structures with ends which can be ligated;
  • V represents construction of a circle by restricting a stem structure at site w, allowing formation and ligation of the product circle. 6
  • This invention is directed to a simple, inexpensive and rapid process for generating multiple linear complements from a single strand, circular nucleic acid and to a process for making such novel circular nucleic acids.
  • An important advantage of generating linear complements from single strand, circular nucleic acids is that the need for differential thermal conditions at each step in the process is alleviated. All steps in the process can be performed isothermally which also alleviates the need for expensive thermocycling devices. Thus, the process is applicable to use for detecting nucleic acids in such areas as medical diagnosis and infectious diseases.
  • the process for generating multiple linear complements from single strand, circular nucleic acid templates involves combining the template with polynucleotide primers, such as an analyte, in a biological sample.
  • the combining step is performed under conditions sufficient for hybridization so that a primer-template is formed between the primer and a complementary region within the circular template and can be used for polymerase extension.
  • the analyte can be, for example, of viral or bacterial origin and may be DNA or RNA.
  • Extending the primer-template with a polymerase such as Klenow fragment generates a linear concatemer of the circular template through strand displacement synthesis.
  • the synthesized DNA segment is thereby replaced with a new strand each time the polymerase passes around the circular template to produce a complementary displacement product.
  • the circular template can contain a cleavage site such as a restriction endonuclease cleavage site.
  • the restriction endonuclease site is incorporated into the complementary displacement product and can be used, when hybridized to a restriction polynucleotide, to cleave the d. --.placement product into unit length linear complements.
  • the restriction polynucleotides are preferably the single strand, circular nucleic acid templates, wherein the restriction site on the circular template has been modified so as to be refractory to endonuclease cleavage. Modification can be accomplished by methylation, for example.
  • linear complements generated by strand displacement synthesis and cleavage can be further used to prime additional circular templates for production of additional linear complements. All components necessary for polymerase extension and cleavage of the displacement product to linear complements remain available for use in additional cycles. In this way, a large number of linear complements can be generated from a very small number of initial polynucleotide primers.
  • linear complements signifies the presence of the analyte.
  • Detection of linear complements or displacement products can be performed by meth * ds known to one skilled in the art.
  • the invention, thf e ore may be used for rapid and efficient detection of i. ectious diseases and diagnoses of genetic disorders.
  • the process for making novel circular nucleic acids for -se in the process for generating linear complemer involves the chemical synthesis of linear polynuclf des and their combination with linking oligonucl « des.
  • the linking oligonucleotides have sequences complementary to the ends of the linear polynucleotides and can be hybridized to the linear polynucleotides. Hybridization of the two types of molecules will bring the 5• and 3• ends of one or more 8 linear polynucleotide together. Ligating the ends of the linear polynucleotides together produces a single strand, circular nucleic acid.
  • single strand, circular nucleic acid template or “circular template” refers to a single strand nucleic acid polymer which has been joined through its 5* and 3' ends to produce a circular molecule.
  • These single strand, circular templates include molecules produced by methods disclosed herein for synthesis of small single-stranded circles (between 30 and 750 nucleotides) as well as molecules produced in vivo or in vitro through bacteriophage replication mechanisms. Circular molecules produced entirely through chemical synthesis are included as well.
  • the circular templates can be either deoxyribonucleic or ribonucleic acids.
  • cleavage site refers to a nucleotide sequence in which the phosphodiester backbone is selectively broken.
  • a nucleotide sequence recognized by a restriction endonuclease is a cleavage site because the enzyme will cut the phosphodiester backbone at selective sites within the sequence.
  • Such cleavage sites may be single or double-stranded, depending on the endonuclease.
  • chemical cleavage sites such as pyri idine and purine cleavage reactions performed in Maxam and Gilbert sequencing, or cleavage through chemical methods such as oxidation as described in United States Patent No. 4,795,700, which is incorporated herein by reference.
  • polynucleotide primer refers to any nucleic acid with a complementary sequence sufficient to hybridize to the single strand, circular template and be used as a substrate for polymerase extension reactions. This term includes an analyte within a mixture of nucleic acids, synthesized oligonucleotides and linear complements produced from displacement products. RNA as well as DNA primers can be used. The length of the primer can vary so long as the 3• terminal nucleotides form sufficient base pairs to effectively prime the template. Therefore, the term "primer-template” as used herein refers to a primer which is hybridized to a single strand, circular template and can be used in polymerase extension reactions.
  • the term "displacement synthesis” refers to polymerase extension reactions in which one strand of a double-stranded region is displaced by the processivity of the enzyme. Effectively, the strand is peeled away from the template simultaneously with new strand synthesis. Therefore, the term “complementary displacement product” or “displacement product” as used herein refers to the displaced complementary strand which is peeled away from the template as the polymerase proceeds around the circular template.
  • restriction polynucleotide refers to a nucleic acid, preferably a single-stranded deoxyribonucleic acid, which encodes a restriction endonuclease site so that when hybridized to a complementary strand it forms a functional restriction endonuclease site.
  • the length of the restriction polynucleotides can vary so long as, when in duplex form, the appropriate restriction enzyme will recognize the sequence and cleave the phosphodiester bonds.
  • Restriction polynucleotides may include linear poly- and oligo ⁇ nucleotides as well as circular nucleic acids such as the circular templates described herein.
  • linear complement refers to the complementary sequence of the single strand, circular template.
  • a linear complement is the extension product from a primer-template substrate and includes concatemers 10 produced by displacement synthesis as well as individual copies of the circle template.
  • blocked refers to modifications of an oligo- or polynucleotide which limits the function of the modified group. Such functions may include polymerization of a nucleotide or nucleotides. Blocking groups can include, for example, attachment of chemical moieties, organic polymers and macromolecules to the oligo- or polynucleotide. Also included is the reverse addition of a nucleotide to the oligo- or polynucleotide. Modifications encompass additions to the nucleotide bases, the sugar moieties and the phosphate backbone.
  • the invention provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single-stranded, circular nucleic acid template; and cleaving the displacement product to generate linear complements of the circle template.
  • single strand, circular templates are first hybridized to polynucleotide primers.
  • the resultant primer-templates are substrates for polymerase directed synthesis of nucleic acids.
  • the template is DNA
  • any of the known DNA polymerases such as E. coli DNA polymerase I, Klenow fragment, T4 or T7 DNA polymerases, modified polymerases, reverse transcriptase.
  • Tag polymerase, Bst polymerase, and T. flavins polymerase can be used to synthesize a complementary DNA strand.
  • the template 11 is RNA
  • reverse transcriptase can be used to synthesize a complementary DNA strand.
  • the invention provides a process for generating multiple copies of a single strand, circular nucleic acid template using the above polymerases.
  • the invention provides for polynucleotide primers which are selected so as to allow strand displacement synthesis by a polymerase.
  • This displacement can be accomplished in a variety of ways.
  • primers can be chosen which are complementary over their entire sequence to the circular template. Extension of the primer around the template will result in displacement of the 5' end of the primer by a polymerase.
  • the resultant displacement product is a linear concatemer which is complementary to the circle template as shown in Figure 2(1). If a completely complementary primer is used, then the polymerase selected should preferably be devoid of 5' to 3' exonuclease activity, such as Klenow fragment. This selection prevents nick translation activity and ensures displacement synthesis.
  • polynucleotide primers can be selected in which the 5' end is non-complementary to sequences contained in the circle template, but the 3* end is complementary to contained sequences and hybridizes to the circle template. Extension of this primer-template around the circle results in displacement synthesis at the juncture of the hybridized and non-hybridized regions sf primer.
  • Polynucleotide primers can also be selected wherein the 5' end of ⁇ he nucleotide primers are blocked. Blocking of the 5* end of a primer, as defined above, allows for displacement synthesis. As with the 5 1 non-complementary primers, a primer modified at its 5' end by, for example, a chemical moiety, will not impede a polymerase's movement, nor will it be recognized by inherent 5' to 3• exonuclease activity found in most polymerases. Therefore, the invention provides a process for generating multiple complements of a circular template wherein the 5' end of the nucleotide primers are non-complementary to the circular template or are blocked so as to allow displacement synthesis by a polymerase.
  • the invention further provides a process of synthesizing single strand, circular nucleic acids containing between 30 and 750 nucleotides by chemically synthesizing a linear polynucleotide; combining the linear polynucleotide with a complementary linking oligonucleotide under conditions sufficient for hybridization; and ligating the linear polynucleotide to produce a single strand, circular nucleic acid. Ligation can be by enzymatic or chemical means.
  • linear polynucleotides are chemically synthesized by methods known to those skilled in the art (e.g. , United States Patent No. 4,500,707, which is incorporated herein by reference) . Current chemical synthesis methods may be used to synthesize linear polynucleotides of up to about 200 bases in length.
  • a linear polynucleotide of about 200 nucleotides is first synthesized.
  • the 5' and 3* ends of the linear molecules are brought together to form circular molecules by hybridization to complementary linking oligonucleotides Figure 3(L) .
  • the linking oligonucleotides are designed such that the 5' end of the linking oligonucleotide is complementary to the 3* end of the synthesized linear polynucleotide and the remaining 3' end of the linking oligonucleotide is complementary to the 5 1 end of the linear polynucleotide.
  • RNA ligase without the use of linking oligonucleotides may be used to ligate a circle since RNA ligase is able to ligate DNA ends together.
  • larger single strand, circular nucleic acids composed of multiple linear polynucleotides of the same sequence may be achieved by varying the concentration of components in the ligation.
  • the invention also provides for the synthesis of single strand, circular nucleic acids, where the circular nucleic acid is synthesized from two or more linear polynucleotides Figure 3(N).
  • Synthesis of larger, single strand, circular nucleic acid templates can be accomplished, for example, by synthesizing two halves of the circle as linear polynucleotides. For example, to generate a 400 nucleotide circle, two shorter linear molecules whose sum is 400 nucleotides are first synthesized.
  • linear molecules are joined together to create a circular molecule in the same fashion as that described above.
  • Complementary linking oligonucleotides are designed to bring the 5' end of one linear molecule and the 3' end of the second linear molecule together.
  • two linking oligonucleotides are needed.
  • One should be complementary to the 5' end of the first linear molecule and to the 3' end of the second molecule.
  • the second linking oligonucleotide should therefore be complementary to the 3* end of the first molecule and to the 5' end of the second.
  • the invention also provides for novel single strand, circular nucleic acid templates, wherein the template comprises between 30 and 750 nucleotides and is made from chemically synthesized oligo- or polynucleotides.
  • single strand, circular nucleic acid templates of the present invention can also be produced by a variety of other methods well known to those skilled in the art.
  • single strand circular templates can be derived through in vivo bacteriophage replication as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, (1989); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, (1987); and Short et al.. Nucleic Acids Research 16:7583-7600 (1988), all of which are incorporated herein by reference.
  • in vitro replication methods can be employed such as those described by Shavitt and Liuneh, J., Bacteriology, 171:3530-3538 (1989), which is incorporated herein by reference.
  • the sequence to be amplified can be cloned into a variety of available phage vectors, such as pBluescriptTM (Stratagene Cloning Systems, La Jolla, CA) or vectors can be constructed such that only pertinent sequences remain.
  • the invention provides a process to generate multiple complements of a circular template, wherein the single strand, circular nucleic acid template is derived from phage replication.
  • circular nucleic acid templates can be generated by in vitro polymerase extension reactions.
  • sequences of preferably between 50 and 2200 nucleotides to be transformed into a circular template are first synthesized as a double-.* anded duplex by priming a linear template and polymerase extension.
  • defined ends of linear duplex can be produced by digesting with restriction endonucleases known to cut at preselected sequences or by using preselected primers in polymerase chain reaction synthesis.
  • the linear extension products can be circularized as a single-stranded molecule by first denaturing the duplex and hybridizing it to a oligonucleotide complementary to each end of the linear template.
  • ligase results in a single strand, circular template.
  • Any linear molecules can be digested with DNases (such as Exo VII) to remove any residual linear fragments, including the complementary strand which does not ligate. Therefore, the invention provides a process to generate multiple complements of a circular template wherein the circular template is between 50 and 2200 nucleotides. Also provided are novel single strand, circular nucleic acid templates wherein the template is between 50 and 220 nucleotides.
  • Synthesis of circular nucleic acids can be accomplished using a combination of the methods described above as well as in conjunction with methods known in the art. For example, methodology using bifunctional phosphorylating reagents as described by Capobianco et al.. Nucleic Acids Research 18:2661-2669 (1990), which is incorporated herein by reference, can be employed for the synthesis of circular templates.
  • This methodology is amenable to synthesis and circularization of nucleotides longer than fovr bases in length or can be used in conjunction with conventional phosphora idite methodology to cyclize longer molecules such as between 50 and 750 nucleotides in length for chemically synthesized linear polynucleotides.
  • the invention additionally provides a process to generate multiple copies of a single strand. circular template, wherein the template is chemically synthesized and is between 30 and 750 nucleotides.
  • the invention provides methods of characterizing small single-stranded circles 50-2200 bases in length, as are produced by any of the above methods. Circularization of linear fragments produces nucleic acid products which migrate as bands with shifted electrophoretic mobilities, usually slower than the linear fragment.
  • Such circles can be distinguished from the initial linear fragment(s) or from other linear by-products as follows: 1) by mobility shift relative to markers; 2) circles do not enzymatically degrade when treated with Exo VII (which requires free 3* or 5' ends); 3) circles can be primed and primers can be extended past the site of ligation; and 4) when annealed with unique restriction polynucleotides at a site other than the ligation site and restricted with the appropriate endonuclease, circles form only one full-length linear fragment. Any non-circular fragments, including the linkers used in producing the circle, will be degraded by Exo VII, cannot extend past the linear terminus and will produce at least two fragments when restricted.
  • the invention provides for a single strand, circular template which has at least one cleavage site.
  • the cleavage sites are used, for example, to reduce the concatemeric displacement product down to individual linear complements. These individual complements correspond to a whole or partial single copy of the circle template.
  • Hybridization of a restriction polynucleotide or a single- stranded circle to the complementary displacement product produces a local duplex region which is the length of the restriction primer.
  • the duplexed region is a substrate for endonucleolytic cleavage when treated with the appropriate endonuclease (i.e., the endonuclease which recognizes the encoded restriction site) . Since the cleavage site is encoded at a predetermined location, restriction of the site produces linear complements of defined length and sequence.
  • the invention also provides for a process to generate multiple complements of a single strand, circular template where the template has a restriction endonuclease site which is capable of being modified so as to inhibit restriction when hybridized in duplex form.
  • a restriction endonuclease site which is capable of being modified so as to inhibit restriction when hybridized in duplex form.
  • the restriction endonuclease activity can be blocked with modified bases, then the appropriate restriction endonuclease will not cleave the DNA when one or both of the strands are modified.
  • endonucleases such as Hpa II, Hae II, Hae III and BstUl are known not to restrict at methylated sites. A particular use for this embodiment is depicted in Figure 2(J) .
  • the circular templates are methylated prior to initial hybridization with the polynucleotide primers by incorporation of modified bases such as 5-methylcytosine or methyladenosine into the linear polynucleotide during chemical synthesis as described by Ono and Ueda, Nucleic Acids Res. (1987) 15:219-232, which is incorporated herein by reference.
  • the circle can also be methylated by a variety of other methods known to one skilled in the art. Such methods include, for example, the use of specific methylase enzymes, such as Hpa II roethylase, to methylate sites in the circle.
  • the invention additionally provides a process to generate multiple complements of a 18 circular template wherein the restriction enzyme site on the template is modified by methylation.
  • Restriction of the displacement product can be accomplished subsequent to, or preferably be performed simultaneously with, primer extension and displacement synthesis.
  • restriction endonucleases can be added at a later time.
  • Displacement synthesis can even be stopped, for example, by heat denaturation of the polymerase or by organic extraction of the reaction.
  • Restriction polynucleotides are hybridized to the displacement product followed by digested with the appropriate restriction endonuclease.
  • restriction polynucleotides and restriction endonucleases are included in the extension reactions.
  • the restriction polynucleotides hybridize to the product and are concomitantly digested by the endonuclease (shown in Figure 2(J)) .
  • restriction polynucleotides can be selected which cannot be used as substrates by a polymerase.
  • These polynucleotides can be either the circular templates described herein which do not have free 3* terminal nucleotides for polymerization or linear molecules which are not substrates for polymerization.
  • polymerase recognition of a primer-template requires that about three terminal nucleotides of the primer be correctly hybridized to the template (Kornberg, A., DNA REPLICATION, W.H. Freeman and Company (1980) , which is incorporated herein by reference) .
  • the use of linear restriction polynucleotides which have non-complementary 3• terminal nucleotides will inefficiently promote polymerase extension reactions.
  • the 3' end of the restriction polynucleotide can be chemically blocked to prevent polymerase extension.
  • Addition of a blocking group such as chemical modification using a 2' ,3•-didedoxy nucleoside at the 3• end, reversing the orientation of the terminal nucleotide or covalently linking a non-hydroxy moiety such as an alkylamine will also allow the simultaneous synthesis and restriction of displacement product without resulting in extension products off of the restriction polynucleotides.
  • the invention provides a process to generate multiple complements of a circular template where the restriction polynucleotides are deoxyribonucleic acids and the 3' end is inhibitory to primer extension by a polymerase.
  • restriction polynucleotides can be further selected so that, once restricted, a fragment of the restriction polynucleotide remains hybridized to the 5'- end of the displacement product.
  • the length of the end of the polynucleotide from the restriction site necessary to retain hybridization under various conditions and temperatures once restricted is known to one skilled in the art, or can be determined without undue experimentation. These procedures are described in detail in Ausubel et al., ibid. Restriction polynucleotides selected in this way allow the linear complements produced after digestion to be used either directly or indirectly as a polynucleotide primer for further strand displacement synthesis.
  • the hybridized portion of the restriction polynucleotide to the 5' end of the linear complement functions in an analogous fashion as the non-complementary or blocked polynucleotide primers described above and therefore allows further hybridization to circular templates and polymerization.
  • the restriction polynucleotides can be further selected so that, once restricted, the fragment hybridized to the 3' end of the linear complement is unstable and does not remain hybridized. This restriction generates a single-stranded 3• end of the linear complement which is available to be recognized as a polymerase substrate when hybridized to a circular template.
  • polynucleotide lengths which are unstable under various conditions and temperatures are known or can be determined by one of ordinary skill in the art.
  • a restriction primer which results in hybridization of only about four nucleotides once it is digested will be unstable.
  • modified circular templates are used as restriction primers, the digested 3' end of the linear complements are already hybridized to the circular templates and can be extended without rehybridization to a circular template.
  • the use of circular templates in this way is advantageous if restriction of the circle is blocked.
  • the invention provides for direct hybridization and primer-template formation between linear complements and single strand, circular template.
  • the invention also provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by: (a) combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; (b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template; (c) cleaving the displacement product to generate linear complements of the circle template; (d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization; 21
  • FIG. 2(K, parts 3-6) shows a schematic diagram depicting the hybridization of linear complements to single strand, circular templates and generation of additional displacement products and linear complements.
  • the invention also provides a process for generating multiple linear complements of a single strand, circular template where all steps are carried out under isothermal conditions.
  • all reactions including, for example, hybridization of polynucleotide primers, restriction polynucleotide-r and linear complement, strand displacement synthesis and restriction endonuclease digestion of displacement products can be performed at the same temperature.
  • this temperature is between about 25* and 70*C, more preferably between about 37*C to 50*C.
  • Isothermal conditions allow multiple and overlapping steps in the cycle to be performed rapidly and simultaneously.
  • the single strand, circular template can be denatured by heat prior to or during hybridization with linear complement.
  • Heat denaturation ensures the availability of all templates for subsequent rounds of 22 synthesis.
  • Linear complements, once restricted, can also be denatured by heat prior to or during hybridization with circular template, ensuring the complete removal of the restriction polynucleotide for efficient primer-template hybridization.
  • the invention utilizes synthetic polynucleotide primers as well as synthetic restriction primers.
  • Chemical synthesis of polynucleotide primers is well known to those skilled in the art. Methods disclosed herein for the synthesis of linear polynucleotides, such as phosphoramidite nucleotide chemistry, are routinely performed on automated synthesizers using protocols and reagents suggested by the manufacturers.
  • the invention further provides a process for generating multiple linear complements of a circular template where the polynucleotide primers comprise a mixture of double and/or single-stranded nucleic acids.
  • the presence of a nucleic acid analyte within a biological sample can be determined by the processes disclosed herein.
  • the analyte can be a nucleic acid from an infectious organism such as a virus or bacteria.
  • the analyte can also be nucleic acid derived from a host organism such as a human.
  • the detection of nucleic acids derived from almost any source allows the invention to be applicable in a large variety of clinical settings. Many infectious diseases and genetic disorders can be easily diagnosed using the invention.
  • Nucleic acids to be analyzed for such diseases and disorders can be isolated from the appropriate tissue or body fluid of an organism and used as polynucleotide primers in the generation of linear complements.
  • the analyte is RNA
  • the appropriate polynucleotide primers and their 3* ends for polymerase extension can be generated by first and second strand cDNA synthesis using preselected first or second strand primers.
  • the analyte is DNA
  • the appropriate 3' ends can be generated for primer extension by digesting the DNA with a preselected restriction enzyme. Accordingly, any nucleic acid analyte can be used, or can be generated using ordinary skills in the art, so long as the 3• terminal nucleotides are sufficiently complementary to the circular template to form a primer-template.
  • any 3'-ends of nucleic acids which are significantly complementary to the single-stranded circular nucleic acid may initiate synthesis of displacement products and linear complements. If such nucleic acids are not the desired polynucleotide primer, such as an analyte target sequence, generation of non-specific background (false positive signal) may be produced. To decrease any non-specific background, the mixture of nucleic acids containing target sequences may be treated with nucleic acids complementary to some portio of the target.
  • Such complementary nucleic acids or catcher nucleic acids may be immobilized on solid supports, such as beads or membranes, or contain a ligand, for example, biotin, which can be used to remove the hybridized catcher and target sequences from solution. After removal of any non-hybridized nucleic acids, the target fragment may now be used to prime the single-stranded, circular nucleic acid.
  • a ligand for example, biotin
  • double-stranded nucleic acids such as DNA or cDNA
  • the strands are separated by denaturation prior to hybridization with the circular templates.
  • Heat or alkaline denaturation are two common procedures for the separation of nucleic acid strands but a variety of other methods are known to one skilled in the art which can also be used.
  • Detection of the analyte in the form of intermediary displacement products or in the form of linear complements can be performed using standard fluorescent staining or hybridization techniques known to one skilled in the art.
  • the invention also provides a process for detecting multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by the steps of: (a) combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template ; (c) cleaving the displacement product to generate linear complements of the circle template; (d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization; (e) repeating steps (b) through (d) at least once to generate linear complements of the circle template; and (g) detecting the linear complements.
  • the invention further provides products such as DNA,
  • These nucleic acids products, or nucleic acids encoding these products can be cloned into a vector for propagation in either encaryotic or procaryotic organisms using ordinary skills in the art. The choice of the vector will depend on the organism in which the nucleic acid will be propagated. Additionally, the cloned products can be expressed in vivo for polypeptide production (using expression vectors) or they can be transcribed and (using transcription vectors) and translated in vitro to produce recombinant polypeptides.
  • Such recombinant polypeptides derived by in vivo or in vitro methods can further be used to generate monoclonal or polyclonal antibodies as described by Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, which is incorporated herein by reference.
  • Circular M13mpl8DNA (single or double stranded) was purchased from U.S. Biochemical (Cleveland, OH). All synthetic oligonucleotides were made using standard phosphoramidite chemistry on an Applied Biosysterns 380A DNA synthesizer (Applied Biosystems, Foster City CA). Purifications of DMT-on oligonucleotides was by "DMTon" reverse phase HPLC using 0.3 x 15 cm C-8 (3 ⁇ ) columns eluting 5 to 30% acetonitrile in 100 mM triethyl-ammonium acetate at 1.0 ml/min.
  • Phosphoramidites of 5-methyl-2' deoxycytidine and 5 » - phosphorylating reagent were purchased from Glen Research, Herdon, VA. Where indicated, oligonucleotide linkers are synthesized with a blocked 3'- end by synthesis on Branched Modifier Icaa-CPG (Glen Research) , which results in oligomers with alkylamines on the 3'-hydroxyl. Size estimation of circles and extension products were based on mobility by agarose (0.5-4%) or polyacrylamide (4-20%) gel electrophoresis; size markers were either Hae III restricted double-stranded Phixl74 or Hae Ill-restricted single-stranded M13 DNA.
  • Total nucleic acid synthesis was quantitated by ionic adsorption of nucleic acid onto DE-81 disks after incorporation of K P- dATP or ⁇ P-dCTP using the method as described in Molecular Clonin ⁇ : A Laborator y Manual, volume 3, 1988 Sambrook et al, eds, p. E18-E19. The number of primers extended in a reaction was quantitated by using M P-end labeled primers of known specific activity.
  • the average number of complements produced from a 26 primed single stranded DNA circle was determined as follows: the circular single stranded DNA is primed by addition of a ten fold molar excess of complementary primer. A primer extension reaction was carried out on the bound primer in the presence of alpha- 32 P-dATP of known specific activity. The total amount of 32 P incorporated into circle complement was measured by spotting 2-5 ⁇ L of the reaction mixture onto Whatman DE81 ion exchange paper. The DE81 paper was washed five times in 0.3M NaP0 4 pH 7.0 for 5 minutes per wash to remove unincorporated 32 P-dATP. The DE81 paper was counted by scintillation counting. The number of adenosine residues per circle complement and the circle concentration was known; allowing calculation of specific activity per circle complement and the number of circle complements produced per circle.
  • This example illustrates the ability of DNA polymerases to displace complement strands produced after extension and the ability of polymerases to incorporate several hundred bases per minute.
  • a 19 ⁇ l reaction volume contained 50 nM M13 model primer (sequence: 5'-dGGTTTTCCCAGTCACGACG) and 5 nM M13mpl8 single-stranded circular DNA (U.S. Biochemical, Cleveland, OH) in Extension Buffer (10 mM Tris, pH 7.4, 10 mM MgCl, 1 mM dithiothreitol (DTT)) containing 200 ⁇ M dGTP, dCTP, dTTP, and alpha- ⁇ P-dATP (6 ⁇ Ci/ ⁇ mol) .
  • the extension was initiated by addition of 1 ⁇ l containing 2 units of DNA polymerase Klenow fragment (BRL, Gaithersburg, MD) .
  • Negative controls consisted of either no primer added or no enzyme added. The extension was incubated for one hour at either 37 * or 50 * C. Total DNA synthesis was determined by spotting 2 ⁇ l aliquots on DE81 anion exchange paper disks (Whatman, Clifton, NJ) , and washed three times in 0.5 M sodium phosphate, pH 7.3. Aliquots of 2-5 ⁇ l were also analyzed by agarose gel electrophoresis followed by autoradiography on XAR film (Kodak, Rochester, NY) to estimate average size of fragments produced by the extension. The results indicated that the average size of circle complement produced was greater than 25,000 bases, or an extension rate of more than 417 bases per minute. This represents more than 18,000 bases of displacement.
  • This example illustrates the construction of a medium size single-stranded circle using recombinant enzymatic methods.
  • M13mpl8 U.S. Biochemical, Cleveland, OH
  • a portion of the solution (90 ⁇ l, 180 ⁇ g of DNA « 76 pmols) was treated in the following manner: 1.5 ⁇ l (750 pmols) of each of two restriction site oligonucleotides were added (500 ⁇ M Bgl II/M13 restriction site oligonucleotide sequence: 5 » -dTGAGAGATCTACAAAGGCTATCAGGTCATTGCCT; AND 10 ⁇ M Bam Hi/Ml3 restriction oligonucleotide, sequence 5'- dTGCATGCCTGCAGGTCGACTCTAGAGGATCCCCG) ; 15 ⁇ l of 10X Universal buffer (Stratagene Cloning Systems, La Jolla, CA) plus 27 ⁇ l H 2 0 was added.
  • the digest was checked for completion on a 1.5% agarose mini-gel with approximately 0.5 ⁇ g of the digested DNA.
  • a preparative 1.5% agarose (FMC SeaKe GTG, Rockland, ME)/TAE was prepared with marker lanes. Agarose gel loading dyes (15.0 ⁇ l) were added to the digest. Ten ⁇ l of this preparation were loaded in the marker lane and the remainder in the preparative well. The sample was electrophoresed in TAE buffer for 1.5 hours at 25 mA.
  • the marker lane was cut from the gel and stained with ethidium bromide in water at a concentration of 0.5 ⁇ g/ l.
  • the 682 bp fragment was located under UV light and then excised from the corresponding location on the gel.
  • the gel slice was loaded onto a Schleicher & Schuell Elutrap (Schleicher & Schuell, Keene, NH) and electroeluted in lx TAE buffer for 4 hours at 130 V. The eluate was recovered and butanol extracted 4 times,
  • Phenol/chloroform/isoamyl alcohol extracted twice and chloroform/isoamyl alcohol extracted one time One tenth volume of 3 M sodium acetate pH 5.4 and 2.5 volumes of 100% ethanol were added and the preparation was incubated in an ethanol/dry ice bath for 20 minutes. The preparation was then centrifuged in a microfuge for 30 minutes at room temperature at 14,000 X G. The supernate was discarded, 0.75 ml of 70% ethanol was added to wash the pellet and the preparation was then re-centrifuged for 5 minutes under the same conditions. Ethanol was removed and the pellet was dried under vacuum for 3 minutes.
  • the dried pellet was redissolved in 100 ⁇ l of H 2 0 and loaded onto a Centricon 100 (Amicon, Danvers, ME). Two mis of 50 mM NaOH/1 mM EDTA were added and the preparation was spun in a fixed angle rotor, (Model SS34; Dupont-Sorvall,
  • Circularization of the 682 bp fragment was performed as follows: The retentate was recovered from Centricon 100 filter apparatus at a total volume of 38 ⁇ l. Forty ⁇ l of 5X ligase buffer (BRL, Gaithersburg, MD) were added. A linker molecule to span both ends of the linear 682 bp fragment was synthesized as described above. The synthesized linker molecule, designated M13/682 ligation linker, had the following sequence: ⁇ 'dCGACTCTAGAGGATCTACAAAGGCTATCAGCAA. One hundred and seven ⁇ l of H 2 0 were added and the preparation was incubated at 65*c for 5 minutes, followed by flash cooling on ice for 5 minutes.
  • T4 DNA Ligase (BRL, Gaithersburg, MD) containing lU/ ⁇ l were added and the preparation was incubated at 16*C for 1 hour. Following incubation, two additional ⁇ ls of linker were added. The preparation was incubated at 65*C for 5 minutes, cooled on ice 5 minutes, and then three ⁇ ls of ligase were added followed by a 1 hour incubation at 16*C. Two additional ⁇ ls of linker were added, followed by another 65 * C incubation, rapid cooling on ice for 5 minutes. Three more ⁇ ls of ligase were added and reaction was incubated at 16*C overnight.
  • This example illustrates the construction of a small single-stranded circle using oligonucleotide synthesis followed by enzymatic ligation to form the circle.
  • a 72 base DNA oligomer with a 5'-phosphate ( sequence:
  • the 3' end of the linker has 3 noncomplementary bases and a blocked 3* end to prevent the linker from extending in a polymerase reaction.
  • This oligomer was used to bring the 5' and 3 1 ends of the 72 base oligomer together to allow for enzymatic ligation.
  • the 72 base oligomer was enzymatically ligated in a lmL reaction volume containing lOuM of 72 base oligomer, 5uM of 33 base linker oligomer, 40mM Tris-Cl pH 7.5, lOmM MgCl 2 , lOmM dithiothreotol, and ImM ATP.
  • the reaction mixture was incubated for 5 minutes at 50°C then cooled to room temperature.
  • 40,000 units of T4 DNA Ligase (New England Biolabs, Beverly, MA) was added to the reaction mixture.
  • the reaction mixture was incubated for 2 hours at room temperature.
  • the linker concentration was brought to lOuM and the reaction mixture was incubated an additional 16 hours at room temperature.
  • the linker concentration was increased to 15uM and the reaction mixture was incubated an additional 2 hours at room temperature.
  • the reaction mixture was electrophoresed at 1000V for 4 hours in a 10% polyacylamide/8M urea gel in lxTBE.
  • the slower migrating circular 72mer product was identified by UV shadowing, electroeluted, ethanol precipitated and quantitated by optical density at 260nm.
  • the circular 72mer was resistant to degradation by Exo VII, and could be primer extended past the ligation site.
  • a synthetic lOlmer oligomer (sequence: 5*- pdGATTAAAATCTCTGACCCGAGCCGATGACTTACTGGC w CG' , CGTT"CGAA''c"CGGA A ⁇ flOTCCCTGGAGTGCGATCTTCCTGAGGCCGATCTGATAGGACATTAT) was synthesized as in Example III.
  • the underlined portion designates the sequence which is complementary to the 33 base linker described below.
  • the lOlmer oligomer contained blocked restriction sites for the restriction endonucleases Hpa II (CCGG) , Bst Bl (TTCGAA) , and Bst Ul (CGCG) .
  • This oligomer was used to bring the 5' and 3* ends of the 101 base oligomer together to allow for enzymatic ligation.
  • the 101 base oligomer was enzymatically ligated and purified as in Example III.
  • the circular lOlmer was resistant to degradation by Exo VII and could be primer extended past the site of ligation.
  • This example illustrates the construction of a small single-stranded circle composed of two core sequences with unique ends enzymatically ligated to form the circle.
  • a synthetic 101 base oligomer (sequence: 5'- 32 pdTTCTAGTTACGCAGGCCCGAGCCGATGACTTACTGGCCGCGTTCGAACCGGAAAG r ⁇ nrC!TGGAGTGCGATCTTCCTGAGGCCGATACTATTTGCACTTTC) was synthesized as in Example III with the same 71 base core sequence but with different 15 base linker sequences on each end of the 101 base oligomer. The different linker sequences, which are underlined, allow for specific ligation between the 101 base oligomer shown above and the 101 base oligomer from Example IV.
  • Two 34 base linkers (sequences: (1) 5'-dCCTGCGTAACTAGAAATAATGTCCTATCAGTTTT- NH 2 and (2) 5'-dTCAGAGATTTTAATCGAAAGTGCAAATAGTCCCC-NH 2 ) that have 15 bases complementary to one end of each 101 base oligomer were also synthesized.
  • the 3* end of the linkers have 4 noncomplementary bases and a 3• amine to prevent the linkers from extending in a polymerase reaction.
  • Each linker w was used to bring the 5' end of one 101 base oligomer and 3' end of the other 101 base oligomer together to allow for enzymatic ligation.
  • the 101 base oligomers were enzymatically ligated and purified into a 202 base oligomer as in Example III except that each 101 base oligomer was at 0.6 ⁇ M and the first linker was at 0.15 ⁇ M starting concentration and increased to 0.75 ⁇ M.
  • the 101 base oligomers were also gel purified before ligation instead of after ligation.
  • the 202 base oligomer was then ligated into a circle as in Example III except the 202 base oligomer was at 0.3 ⁇ M and the second linker was at 0.15 ⁇ M starting concentration and increased to 1.2 ⁇ M.
  • This example illustrates the ability of DNA polymerases to displace complement strands produced after extension, and the ability of polymerases to incorporate several hundred bases per minute into a medium-sized single-stranded circle.
  • a primer extension reaction was carried out and extension products determined as described in Example I. Extension reactions for the circular 682 bp single strand, nucleic acid were performed using free nucleotides, a DNA Polymerase (BRL, Gaithersburg, MD) , a synthetic K P labeled primer fragment (5000 cp /fmole) and T4 Polynucleotide Kinase (New England Biolabs, Beverly, MA ) .
  • a primer extension reaction was carried out as in Example I except a different primer was used (sequence: 5•-dACAAGGACCAAAAGAACCTTTTAGAGACTATGTAGAC) .
  • the 19 bases on the 3' end are complementary to the 72 base circle but the 18 bases on the 5* end are not complementary to the circle.
  • the average size of circle complement produced using a 72-base single-stranded circle was 150 to 250 bases.
  • This example illustrates the ability of Sau 3A endonuclease to restrict the amplified product of a 7300- base single-stranded circle to generate linear complements for use as secondary primers in the next cycle of extension reaction.
  • a 19 ⁇ l reaction volume contained 50 nM M13mpl8 single-stranded circle (U.S. Biochemical, Cleveland, OH) and 5 nM M13 primer (100 fmole) in extension buffer (20 mM Tris pH 7.5, 10 mM MgCl 2 , 25 mM NaCl, 6.5 mM DTT) containing 200 ⁇ M dGTP, dCTP, dATP, dTTP and 0.33 ⁇ M of alpha ⁇ P- dATP. The final specific activity of ⁇ P-dATP was 9,000 cpm/pmole.
  • the extension was initiated by addition of 1 ⁇ l of DNA polymerase Klenow fragment (BRL, Gaithersburg, MD, 6 units/ ⁇ l) for 1 hour at 50*C.
  • 2 ⁇ l of 8 units/ ⁇ l Sau3A I enzyme (BRL, Gaithersburg, MD) were added to the 20 ⁇ l reaction mix and allowed to digest for 1 hour at 37'C.
  • 4 ⁇ l of the 20 ⁇ l reaction mix was transferred into a new tube and denatured for 2 minutes at 100*C in a heat block (silicon oil/sand or boiling water) , followed by chilling in a dry ice bath for 1 minute.
  • a primer extension reaction was carried out as in Example VII except Taq DNA Polymerase (Cetus, Emeryville, CA) was used at 60'C instead o: Klenow at 37*C.
  • the extended product was brought to 5 mM in DTT and 1 ⁇ M in a 38 base restriction linker (sequence: 5'- dTGACTATCCTGTAATAAAGATCAATGCGTCCGGTCTAC-NH 2 ) .
  • the restriction linker is complementary to the circle complement and renders it double-stranded. 10 units of Hpa II restriction endonuclease were added and the reaction mix was incubated 30 minutes at 37*C.
  • the product was visualized by autoradiography.
  • the circle complement was cleaved into 72 base fragments following this procedure.

Abstract

A process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site is described. The process consists of combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; extending the polynucleotide primer more than once around the circle to generate a complementary displacement of more than one contiguous complement of the single strand, circular nucleic acid template. Also described is a process of synthesizing novel single strand, circular nucleic acids between 30 and 2200 nucleotides. The process consists of synthesizing a linear polynucleotide; combining the linear polynucleotide with a complementary linking oligonucleotide under conditions sufficient for hybridization; and ligating the linear polynucleotide to produce a single strand, circular nucleic acid.

Description

CIRCULAR EXTENSION FOR GENERATING MULTIPLE NUCLEIC ACID COMPLEMENTS
BACKGROUND OF THE INVENTION
This invention relates generally to the generation of multiple complementary copies of a nucleic acid and, more particularly, to the generation of such complementary copies using novel circular templates.
Recombinant DNA techniques have revolutionized molecular biology and genetics by permitting the isolation and characterization of specific DNA fragments. Of major impact has been the exponential amplification of small amounts of DNA by a technique known as the polymerase chain reaction (PCR) . The sensitivity, speed and versatility of PCR makes this technique amenable to a wide variety of applications such as medical diagnostics, human genetics, forensic science and other disciplines of the biological sciences.
PCR is based on the enzymatic amplification of a DNA sequence that is flanked by two oligonucleotide primers which hybridize to opposite strands of the target sequence. The primers are oriented with their 3' ends pointing towards each other. Repeated cycles of heat denaturation of the template, annealing of the primers to their complementary sequences and extension of the annealed primers with a DNA polymerase result in the amplification of the segment defined by the 5' ends of the PCR primers. Since the extension product of each primer can serve as a template for the other primer, each cycle results in the exponential accu-nu tion of the specific target fragment, up to several mill unfold in a few hours. The method can be used with a complex template such as genomic DNA and can amplify a single-copy gene contained therein. It is also capable of amplifying a single molecule of target DNA in a
Figure imgf000004_0001
complex mixture of RNAs or DNAs and can, under some conditions, produce fragments up to ten kbp long. The PCR technology is the subject matter of United States Patent Nos. 4,683,195, 4,800,159, 4,754,065, and 4,683,202 all of which are incorporated herein by reference.
While the possible applications of PCR are numerous, they are limited to those situations where the DNA sequence is known with sufficient specificity to design two primers which hybridize to opposite strands of the target sequence. Moreover, the repetitive cycles of heating and cooling, primer hybridization and polymerization are time consuming and optimally performed on expensive, automated thermocycling devices.
Since the advent of PCR, several additional methods have been devised to amplify the copy number of a target sequence. Such methods employ a variety of strategies to achieve the amplification of a small amount of target sequence; however, all have inherent drawbacks.
The ligation chain reaction (LCR) is one such method. See PCT publication WO 89/12696, which is incorporated herein by reference. LCR uses a ligase enzyme to join preformed stretches of DNA, termed "probes." Once these probes find their complementary target sequences and anneal to them, the ligase joins the target sequences together, setting up a situation analogous to that found in PCR: two templates are formed, both of which can serve in the next cycle to generate more copies of the target sequence.
Qβ replicase is another alternative for exponentially amplifying a target sequence. This method relies on the ability of the enzyme Qβ replicase to generate copies of recombinant RNA molecules. Qβ replicase is an RNA-directed tRNA polymerase of bacteriophage Qβ. The sequence to be amplified is cloned into a gene coding for a natural template of Qβ, such as MDV-1 RNA, and produced as a recombinant RNA. For target amplification, the recombinant RNAs hybridize to complementary DNA and serve as templates for RNA synthesis. See Kramer and Lazardi, Nature 339:401- 402 (1989) , which is incorporated herein by reference.
Transcription-based amplification (TAS) systems have also been developed to amplify the copy number of a target sequence, as described in PCT publication WO 88/10315. The cycle begins with the synthesis of cDNA from a target RNA sequence. TAS employs specialized 5* primers which contain a RNA polymerase promoter sequence. The use of these primers results in a promoter sequence being incorporated into the double-stranded product. Transcription from the promoter results in the production of multiple RNA copies. These copies can then be reprimed for additional rounds of cDNA synthesis and transcription. A disadvantage to this method is that it requires accurate execution of at least three enzymatic steps. Therefore, full length products may be difficult to obtain.
Finally, enhancement of target sequences by priming, extension, restriction and reannealing of a linear fragment containing multiple copies of the target sequence has been described. See Becker et al., EPA No. 0 300 796, which is incorporated herein by reference. Although this method generates additional copies of target sequence with each cycle, it has a major disadvantage in that the template, which consists of multiple copies of the target sequence, is destroyed by restriction at the end of each cycle and cannot be reused. Moreover, multiple copies must be present in each template to provide any increase in copies, and product transcripts are of highly variable length.
Most of the methods described above rely on thermal cyclization for denaturating and reannealing of products and templates. Methods such as the Qβ replicase technique additionally require specialized recombinant RNA templates. Moreover, all methods employ linear templates, some of which are specially constructed to contain repetitive copies of the sequence to be amplified.
There thus exists a need for a method to generate multiple copies of a target sequence without the use of degenerative or specialized linear templates and without time consuming thermal cyclizations. Such a method would be of critical importance to increasing the efficiency of medical diagnosis. The present invention satisfies this need through the use of novel circular templates and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site. The process includes combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; and extending the polynucleotide primer more than once around the circle to generate a complementary displacement of more than one contiguous complement of the single strand, circular nucleic acid template. The invention further provides a process of synthesizing novel single strand, circular nucleic acids between 30 and 2200 nucleotides, by synthesizing a linear polynucleotide and ligating the linear polynucleotide to produce a single strand, circular nucleic acid. 5
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 is a schematic diagram of a single-stranded circle. A represents a target sequence, ""--1000 bases in length, complementary to the polynucleoti--. primer; B and C represent sequences, 0-400 bases in length, which are used as detection sequences for circle complement; d-f represent linking sequences of 0-100 bases in length. Any of A-e may contain one or more restriction sites.
FIGURE 2 is a schematic diagram for generating multiple nucleic acid complements. G represents single- stranded circle primed for extension by a target polynucleotide; H represents excess single-stranded circle; I represents G extended by polymerizing enzymes after displacement to form multiple linear concatemers; J represents I cleaved into smaller fragments; K represents H primed by fragments from J; Reaction 1 is extension of primer by polymerizing enzymes; Reaction 2 is cleavage of I to form J; Reaction 3 is reannealing of fragments from J to circles H.
FIGURE 3 is a schematic diagram of constructs for making single-stranded circles. L represents one linear fragment circularized by linker m before ligation; N represents formation of a circle composed of two or -more fragments o and p, each 15-1100 bases in length which may be similar or different in sequence; Q represents formation of a circle capable of forming at least one stem structure by ligation of two subunits containing loops r and s; T represents formation of a circle capable of forming at least one stem structure by ligation of a single linear fragment containing loops r and s; U represents formation of a circle capable of forming one or more stem structures with ends which can be ligated; V represents construction of a circle by restricting a stem structure at site w, allowing formation and ligation of the product circle. 6
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to a simple, inexpensive and rapid process for generating multiple linear complements from a single strand, circular nucleic acid and to a process for making such novel circular nucleic acids. An important advantage of generating linear complements from single strand, circular nucleic acids is that the need for differential thermal conditions at each step in the process is alleviated. All steps in the process can be performed isothermally which also alleviates the need for expensive thermocycling devices. Thus, the process is applicable to use for detecting nucleic acids in such areas as medical diagnosis and infectious diseases.
In one embodiment, the process for generating multiple linear complements from single strand, circular nucleic acid templates involves combining the template with polynucleotide primers, such as an analyte, in a biological sample. The combining step is performed under conditions sufficient for hybridization so that a primer-template is formed between the primer and a complementary region within the circular template and can be used for polymerase extension. The analyte can be, for example, of viral or bacterial origin and may be DNA or RNA.
Extending the primer-template with a polymerase such as Klenow fragment generates a linear concatemer of the circular template through strand displacement synthesis. The synthesized DNA segment is thereby replaced with a new strand each time the polymerase passes around the circular template to produce a complementary displacement product.
The circular template can contain a cleavage site such as a restriction endonuclease cleavage site. The restriction endonuclease site is incorporated into the complementary displacement product and can be used, when hybridized to a restriction polynucleotide, to cleave the d. --.placement product into unit length linear complements. The restriction polynucleotides are preferably the single strand, circular nucleic acid templates, wherein the restriction site on the circular template has been modified so as to be refractory to endonuclease cleavage. Modification can be accomplished by methylation, for example.
The linear complements generated by strand displacement synthesis and cleavage can be further used to prime additional circular templates for production of additional linear complements. All components necessary for polymerase extension and cleavage of the displacement product to linear complements remain available for use in additional cycles. In this way, a large number of linear complements can be generated from a very small number of initial polynucleotide primers.
If the polynucleotide primers are, for example, analytes in a biological sample, then the production of linear complements signifies the presence of the analyte. Detection of linear complements or displacement products can be performed by meth*ds known to one skilled in the art. The invention, thf e ore, may be used for rapid and efficient detection of i. ectious diseases and diagnoses of genetic disorders.
In another embodiment, the process for making novel circular nucleic acids for -se in the process for generating linear complemer involves the chemical synthesis of linear polynuclf des and their combination with linking oligonucl« des. The linking oligonucleotides have sequences complementary to the ends of the linear polynucleotides and can be hybridized to the linear polynucleotides. Hybridization of the two types of molecules will bring the 5• and 3• ends of one or more 8 linear polynucleotide together. Ligating the ends of the linear polynucleotides together produces a single strand, circular nucleic acid.
As used herein, the term "single strand, circular nucleic acid template" or "circular template" refers to a single strand nucleic acid polymer which has been joined through its 5* and 3' ends to produce a circular molecule. These single strand, circular templates include molecules produced by methods disclosed herein for synthesis of small single-stranded circles (between 30 and 750 nucleotides) as well as molecules produced in vivo or in vitro through bacteriophage replication mechanisms. Circular molecules produced entirely through chemical synthesis are included as well. The circular templates can be either deoxyribonucleic or ribonucleic acids.
As used herein, the term "cleavage site" refers to a nucleotide sequence in which the phosphodiester backbone is selectively broken. For example, a nucleotide sequence recognized by a restriction endonuclease is a cleavage site because the enzyme will cut the phosphodiester backbone at selective sites within the sequence. Such cleavage sites may be single or double-stranded, depending on the endonuclease. Also included are chemical cleavage sites such as pyri idine and purine cleavage reactions performed in Maxam and Gilbert sequencing, or cleavage through chemical methods such as oxidation as described in United States Patent No. 4,795,700, which is incorporated herein by reference.
As used herein, the term "polynucleotide primer" refers to any nucleic acid with a complementary sequence sufficient to hybridize to the single strand, circular template and be used as a substrate for polymerase extension reactions. This term includes an analyte within a mixture of nucleic acids, synthesized oligonucleotides and linear complements produced from displacement products. RNA as well as DNA primers can be used. The length of the primer can vary so long as the 3• terminal nucleotides form sufficient base pairs to effectively prime the template. Therefore, the term "primer-template" as used herein refers to a primer which is hybridized to a single strand, circular template and can be used in polymerase extension reactions.
As used herein, the term "displacement synthesis" refers to polymerase extension reactions in which one strand of a double-stranded region is displaced by the processivity of the enzyme. Effectively, the strand is peeled away from the template simultaneously with new strand synthesis. Therefore, the term "complementary displacement product" or "displacement product" as used herein refers to the displaced complementary strand which is peeled away from the template as the polymerase proceeds around the circular template.
As used herein, the term "restriction polynucleotide" refers to a nucleic acid, preferably a single-stranded deoxyribonucleic acid, which encodes a restriction endonuclease site so that when hybridized to a complementary strand it forms a functional restriction endonuclease site. The length of the restriction polynucleotides can vary so long as, when in duplex form, the appropriate restriction enzyme will recognize the sequence and cleave the phosphodiester bonds. Restriction polynucleotides may include linear poly- and oligo¬ nucleotides as well as circular nucleic acids such as the circular templates described herein.
As used herein, the term "linear complement" refers to the complementary sequence of the single strand, circular template. A linear complement is the extension product from a primer-template substrate and includes concatemers 10 produced by displacement synthesis as well as individual copies of the circle template.
As used herein, the term "blocked" refers to modifications of an oligo- or polynucleotide which limits the function of the modified group. Such functions may include polymerization of a nucleotide or nucleotides. Blocking groups can include, for example, attachment of chemical moieties, organic polymers and macromolecules to the oligo- or polynucleotide. Also included is the reverse addition of a nucleotide to the oligo- or polynucleotide. Modifications encompass additions to the nucleotide bases, the sugar moieties and the phosphate backbone.
The invention provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single-stranded, circular nucleic acid template; and cleaving the displacement product to generate linear complements of the circle template.
As shown in Figure 2(G), single strand, circular templates are first hybridized to polynucleotide primers. The resultant primer-templates are substrates for polymerase directed synthesis of nucleic acids. For example, if the template is DNA, then any of the known DNA polymerases such as E. coli DNA polymerase I, Klenow fragment, T4 or T7 DNA polymerases, modified polymerases, reverse transcriptase. Tag polymerase, Bst polymerase, and T. flavins polymerase can be used to synthesize a complementary DNA strand. Alternatively, if the template 11 is RNA, reverse transcriptase can be used to synthesize a complementary DNA strand. The invention provides a process for generating multiple copies of a single strand, circular nucleic acid template using the above polymerases.
The invention provides for polynucleotide primers which are selected so as to allow strand displacement synthesis by a polymerase. This displacement can be accomplished in a variety of ways. For example, primers can be chosen which are complementary over their entire sequence to the circular template. Extension of the primer around the template will result in displacement of the 5' end of the primer by a polymerase. The resultant displacement product is a linear concatemer which is complementary to the circle template as shown in Figure 2(1). If a completely complementary primer is used, then the polymerase selected should preferably be devoid of 5' to 3' exonuclease activity, such as Klenow fragment. This selection prevents nick translation activity and ensures displacement synthesis.
Alternatively, polynucleotide primers can be selected in which the 5' end is non-complementary to sequences contained in the circle template, but the 3* end is complementary to contained sequences and hybridizes to the circle template. Extension of this primer-template around the circle results in displacement synthesis at the juncture of the hybridized and non-hybridized regions sf primer.
Polynucleotide primers can also be selected wherein the 5' end of ^he nucleotide primers are blocked. Blocking of the 5* end of a primer, as defined above, allows for displacement synthesis. As with the 51 non-complementary primers, a primer modified at its 5' end by, for example, a chemical moiety, will not impede a polymerase's movement, nor will it be recognized by inherent 5' to 3• exonuclease activity found in most polymerases. Therefore, the invention provides a process for generating multiple complements of a circular template wherein the 5' end of the nucleotide primers are non-complementary to the circular template or are blocked so as to allow displacement synthesis by a polymerase.
The invention further provides a process of synthesizing single strand, circular nucleic acids containing between 30 and 750 nucleotides by chemically synthesizing a linear polynucleotide; combining the linear polynucleotide with a complementary linking oligonucleotide under conditions sufficient for hybridization; and ligating the linear polynucleotide to produce a single strand, circular nucleic acid. Ligation can be by enzymatic or chemical means.
The linear polynucleotides are chemically synthesized by methods known to those skilled in the art (e.g. , United States Patent No. 4,500,707, which is incorporated herein by reference) . Current chemical synthesis methods may be used to synthesize linear polynucleotides of up to about 200 bases in length.
To generate a single strand, circular nucleic acid of about 200 nucleotides, a linear polynucleotide of about 200 nucleotides is first synthesized. The 5' and 3* ends of the linear molecules are brought together to form circular molecules by hybridization to complementary linking oligonucleotides Figure 3(L) . The linking oligonucleotides are designed such that the 5' end of the linking oligonucleotide is complementary to the 3* end of the synthesized linear polynucleotide and the remaining 3' end of the linking oligonucleotide is complementary to the 51 end of the linear polynucleotide. The ends of the linear polynucleotide which have been brought together in this way are covalently joined by ligation. Alternatively, the use of RNA ligase without the use of linking oligonucleotides may be used to ligate a circle since RNA ligase is able to ligate DNA ends together. Additionally, larger single strand, circular nucleic acids composed of multiple linear polynucleotides of the same sequence may be achieved by varying the concentration of components in the ligation.
The invention also provides for the synthesis of single strand, circular nucleic acids, where the circular nucleic acid is synthesized from two or more linear polynucleotides Figure 3(N). Synthesis of larger, single strand, circular nucleic acid templates can be accomplished, for example, by synthesizing two halves of the circle as linear polynucleotides. For example, to generate a 400 nucleotide circle, two shorter linear molecules whose sum is 400 nucleotides are first synthesized.
The linear molecules are joined together to create a circular molecule in the same fashion as that described above. Complementary linking oligonucleotides are designed to bring the 5' end of one linear molecule and the 3' end of the second linear molecule together. For example, to bring together two linear molecules which contain different terminal sequences at each of the four ends, two linking oligonucleotides are needed. One should be complementary to the 5' end of the first linear molecule and to the 3' end of the second molecule. The second linking oligonucleotide should therefore be complementary to the 3* end of the first molecule and to the 5' end of the second. If the 5" and 3' ends of one linear molecule are identical or similiar in sequence to the 5' and 3* ends, respectively of the second linear molecule, then only a single complementary oligonucleotide may be used. Hybridization of the complementary oligonucleotides to the linear molecules will bring together the four ends of the molecules to form a non-covalently closed circle. The phosphodiester backbone can be ligated together to form covalently closed, single-stranded circles. In a similar manner, circles composed of three or more linear polynucleotide precursors can be produced. Additionally, alternative strategies for . ligation of linear polynucleotides into circles may be employed and are shown in Figure 3. Therefore, the invention also provides for novel single strand, circular nucleic acid templates, wherein the template comprises between 30 and 750 nucleotides and is made from chemically synthesized oligo- or polynucleotides.
The single strand, circular nucleic acid templates of the present invention can also be produced by a variety of other methods well known to those skilled in the art. For example, single strand circular templates can be derived through in vivo bacteriophage replication as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, (1989); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, (1987); and Short et al.. Nucleic Acids Research 16:7583-7600 (1988), all of which are incorporated herein by reference. Alternatively, in vitro replication methods can be employed such as those described by Shavitt and Liuneh, J., Bacteriology, 171:3530-3538 (1989), which is incorporated herein by reference. The sequence to be amplified can be cloned into a variety of available phage vectors, such as pBluescript™ (Stratagene Cloning Systems, La Jolla, CA) or vectors can be constructed such that only pertinent sequences remain. The invention provides a process to generate multiple complements of a circular template, wherein the single strand, circular nucleic acid template is derived from phage replication.
Alternatively, circular nucleic acid templates can be generated by in vitro polymerase extension reactions. For 15 example, sequences of preferably between 50 and 2200 nucleotides to be transformed into a circular template are first synthesized as a double-.* anded duplex by priming a linear template and polymerase extension. Defined ends of linear duplex can be produced by digesting with restriction endonucleases known to cut at preselected sequences or by using preselected primers in polymerase chain reaction synthesis. The linear extension products can be circularized as a single-stranded molecule by first denaturing the duplex and hybridizing it to a oligonucleotide complementary to each end of the linear template. Treatment of this structure with ligase results in a single strand, circular template. Any linear molecules can be digested with DNases (such as Exo VII) to remove any residual linear fragments, including the complementary strand which does not ligate. Therefore, the invention provides a process to generate multiple complements of a circular template wherein the circular template is between 50 and 2200 nucleotides. Also provided are novel single strand, circular nucleic acid templates wherein the template is between 50 and 220 nucleotides.
Synthesis of circular nucleic acids can be accomplished using a combination of the methods described above as well as in conjunction with methods known in the art. For example, methodology using bifunctional phosphorylating reagents as described by Capobianco et al.. Nucleic Acids Research 18:2661-2669 (1990), which is incorporated herein by reference, can be employed for the synthesis of circular templates. This methodology is amenable to synthesis and circularization of nucleotides longer than fovr bases in length or can be used in conjunction with conventional phosphora idite methodology to cyclize longer molecules such as between 50 and 750 nucleotides in length for chemically synthesized linear polynucleotides. Thus, the invention additionally provides a process to generate multiple copies of a single strand. circular template, wherein the template is chemically synthesized and is between 30 and 750 nucleotides.
In another aspect, the invention provides methods of characterizing small single-stranded circles 50-2200 bases in length, as are produced by any of the above methods. Circularization of linear fragments produces nucleic acid products which migrate as bands with shifted electrophoretic mobilities, usually slower than the linear fragment. Such circles can be distinguished from the initial linear fragment(s) or from other linear by-products as follows: 1) by mobility shift relative to markers; 2) circles do not enzymatically degrade when treated with Exo VII (which requires free 3* or 5' ends); 3) circles can be primed and primers can be extended past the site of ligation; and 4) when annealed with unique restriction polynucleotides at a site other than the ligation site and restricted with the appropriate endonuclease, circles form only one full-length linear fragment. Any non-circular fragments, including the linkers used in producing the circle, will be degraded by Exo VII, cannot extend past the linear terminus and will produce at least two fragments when restricted.
The invention provides for a single strand, circular template which has at least one cleavage site. The cleavage sites are used, for example, to reduce the concatemeric displacement product down to individual linear complements. These individual complements correspond to a whole or partial single copy of the circle template. Hybridization of a restriction polynucleotide or a single- stranded circle to the complementary displacement product produces a local duplex region which is the length of the restriction primer. The duplexed region is a substrate for endonucleolytic cleavage when treated with the appropriate endonuclease (i.e., the endonuclease which recognizes the encoded restriction site) . Since the cleavage site is encoded at a predetermined location, restriction of the site produces linear complements of defined length and sequence.
The invention also provides for a process to generate multiple complements of a single strand, circular template where the template has a restriction endonuclease site which is capable of being modified so as to inhibit restriction when hybridized in duplex form. For example, if the restriction endonuclease activity can be blocked with modified bases, then the appropriate restriction endonuclease will not cleave the DNA when one or both of the strands are modified. For example, endonucleases such as Hpa II, Hae II, Hae III and BstUl are known not to restrict at methylated sites. A particular use for this embodiment is depicted in Figure 2(J) . Restriction of the displacement product down to individual linear complements as described above will also restrict the circle template to a linear form unless the site on the template is refractory to digestion. For example, modification of a Hpa II site on the circle template by methylation as described by Nelson and McClelland, Nucleic Acids Research (1987), 15:219-230, and incorporated herein by reference, inhibits digestion of the hemi-methylated DNA and therefore preserves the structure of the circular template. Preferably, the circular templates are methylated prior to initial hybridization with the polynucleotide primers by incorporation of modified bases such as 5-methylcytosine or methyladenosine into the linear polynucleotide during chemical synthesis as described by Ono and Ueda, Nucleic Acids Res. (1987) 15:219-232, which is incorporated herein by reference. The circle can also be methylated by a variety of other methods known to one skilled in the art. Such methods include, for example, the use of specific methylase enzymes, such as Hpa II roethylase, to methylate sites in the circle. Therefore, the invention additionally provides a process to generate multiple complements of a 18 circular template wherein the restriction enzyme site on the template is modified by methylation. When it is not known if restriction enzyme activity can be blocked, simple procedures using oligonucleotide duplexes in solution can easily ascertain how much enzyme activity is reduced by site modification.
Restriction of the displacement product can be accomplished subsequent to, or preferably be performed simultaneously with, primer extension and displacement synthesis. In the former case, restriction endonucleases can be added at a later time. Displacement synthesis can even be stopped, for example, by heat denaturation of the polymerase or by organic extraction of the reaction. Restriction polynucleotides are hybridized to the displacement product followed by digested with the appropriate restriction endonuclease. In the latter case, restriction polynucleotides and restriction endonucleases are included in the extension reactions. As the displacement product is produced, the restriction polynucleotides hybridize to the product and are concomitantly digested by the endonuclease (shown in Figure 2(J)) .
During simultaneous synthesis and restriction, if extension products resulting from primer extension of the hybridized restriction polynucleotides are undesirable, then restriction polynucleotides can be selected which cannot be used as substrates by a polymerase. These polynucleotides can be either the circular templates described herein which do not have free 3* terminal nucleotides for polymerization or linear molecules which are not substrates for polymerization. For example, polymerase recognition of a primer-template requires that about three terminal nucleotides of the primer be correctly hybridized to the template (Kornberg, A., DNA REPLICATION, W.H. Freeman and Company (1980) , which is incorporated herein by reference) . Therefore, the use of linear restriction polynucleotides which have non-complementary 3• terminal nucleotides will inefficiently promote polymerase extension reactions. Alternatively, the 3' end of the restriction polynucleotide can be chemically blocked to prevent polymerase extension. Addition of a blocking group such as chemical modification using a 2' ,3•-didedoxy nucleoside at the 3• end, reversing the orientation of the terminal nucleotide or covalently linking a non-hydroxy moiety such as an alkylamine will also allow the simultaneous synthesis and restriction of displacement product without resulting in extension products off of the restriction polynucleotides. Thus, the invention provides a process to generate multiple complements of a circular template where the restriction polynucleotides are deoxyribonucleic acids and the 3' end is inhibitory to primer extension by a polymerase.
The restriction polynucleotides can be further selected so that, once restricted, a fragment of the restriction polynucleotide remains hybridized to the 5'- end of the displacement product. The length of the end of the polynucleotide from the restriction site necessary to retain hybridization under various conditions and temperatures once restricted is known to one skilled in the art, or can be determined without undue experimentation. These procedures are described in detail in Ausubel et al., ibid. Restriction polynucleotides selected in this way allow the linear complements produced after digestion to be used either directly or indirectly as a polynucleotide primer for further strand displacement synthesis. The hybridized portion of the restriction polynucleotide to the 5' end of the linear complement functions in an analogous fashion as the non-complementary or blocked polynucleotide primers described above and therefore allows further hybridization to circular templates and polymerization. The restriction polynucleotides can be further selected so that, once restricted, the fragment hybridized to the 3' end of the linear complement is unstable and does not remain hybridized. This restriction generates a single-stranded 3• end of the linear complement which is available to be recognized as a polymerase substrate when hybridized to a circular template. Again, polynucleotide lengths which are unstable under various conditions and temperatures are known or can be determined by one of ordinary skill in the art. For example, at 37*C, which is the optimal temperature for a polymerase, a restriction primer which results in hybridization of only about four nucleotides once it is digested will be unstable. Additionally, if modified circular templates are used as restriction primers, the digested 3' end of the linear complements are already hybridized to the circular templates and can be extended without rehybridization to a circular template. The use of circular templates in this way is advantageous if restriction of the circle is blocked. Thus, the invention provides for direct hybridization and primer-template formation between linear complements and single strand, circular template.
The invention also provides a process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by: (a) combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; (b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template; (c) cleaving the displacement product to generate linear complements of the circle template; (d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization; 21
(e) repeating steps (b) through (d) at least once to generate linear complements of the circle template.
By subsequent hybridization, or preferably simultaneous hybridization, of the initially produced linear complements, the products of more than one cycle (steps a through c above which correspond to Figure 2, steps G through J) of linear complements can be generated. Figure 2(K, parts 3-6) shows a schematic diagram depicting the hybridization of linear complements to single strand, circular templates and generation of additional displacement products and linear complements. Thus, repetitive cycles of priming, strand displacement synthesis, cleaving of the linear complements and repri ing with linear complement exponentially amplifies the copy number of the initial polynucleotide primer. Generation of multiple complements of the circle template indicates the presence of the initial polynucleotide primer.
The invention also provides a process for generating multiple linear complements of a single strand, circular template where all steps are carried out under isothermal conditions. Using the preferred embodiments of the present invention, all reactions including, for example, hybridization of polynucleotide primers, restriction polynucleotide-r and linear complement, strand displacement synthesis and restriction endonuclease digestion of displacement products can be performed at the same temperature. Preferably this temperature is between about 25* and 70*C, more preferably between about 37*C to 50*C. Isothermal conditions allow multiple and overlapping steps in the cycle to be performed rapidly and simultaneously.
Alternatively, the single strand, circular template can be denatured by heat prior to or during hybridization with linear complement. Heat denaturation ensures the availability of all templates for subsequent rounds of 22 synthesis. Linear complements, once restricted, can also be denatured by heat prior to or during hybridization with circular template, ensuring the complete removal of the restriction polynucleotide for efficient primer-template hybridization.
The invention utilizes synthetic polynucleotide primers as well as synthetic restriction primers. Chemical synthesis of polynucleotide primers is well known to those skilled in the art. Methods disclosed herein for the synthesis of linear polynucleotides, such as phosphoramidite nucleotide chemistry, are routinely performed on automated synthesizers using protocols and reagents suggested by the manufacturers.
The invention further provides a process for generating multiple linear complements of a circular template where the polynucleotide primers comprise a mixture of double and/or single-stranded nucleic acids.
For example, the presence of a nucleic acid analyte within a biological sample can be determined by the processes disclosed herein. The analyte can be a nucleic acid from an infectious organism such as a virus or bacteria. The analyte can also be nucleic acid derived from a host organism such as a human. The detection of nucleic acids derived from almost any source allows the invention to be applicable in a large variety of clinical settings. Many infectious diseases and genetic disorders can be easily diagnosed using the invention.
Nucleic acids to be analyzed for such diseases and disorders can be isolated from the appropriate tissue or body fluid of an organism and used as polynucleotide primers in the generation of linear complements. If the analyte is RNA, the appropriate polynucleotide primers and their 3* ends for polymerase extension can be generated by first and second strand cDNA synthesis using preselected first or second strand primers. If the analyte is DNA, the appropriate 3' ends can be generated for primer extension by digesting the DNA with a preselected restriction enzyme. Accordingly, any nucleic acid analyte can be used, or can be generated using ordinary skills in the art, so long as the 3• terminal nucleotides are sufficiently complementary to the circular template to form a primer-template.
In the process of the present invention, any 3'-ends of nucleic acids which are significantly complementary to the single-stranded circular nucleic acid may initiate synthesis of displacement products and linear complements. If such nucleic acids are not the desired polynucleotide primer, such as an analyte target sequence, generation of non-specific background (false positive signal) may be produced. To decrease any non-specific background, the mixture of nucleic acids containing target sequences may be treated with nucleic acids complementary to some portio of the target. Such complementary nucleic acids or catcher nucleic acids may be immobilized on solid supports, such as beads or membranes, or contain a ligand, for example, biotin, which can be used to remove the hybridized catcher and target sequences from solution. After removal of any non-hybridized nucleic acids, the target fragment may now be used to prime the single-stranded, circular nucleic acid. Such affinity selection of target polynucleotide primer greatly reduces non-specific backgrounds.
If double-stranded nucleic acids, such as DNA or cDNA, are used or have been generated to use as polynucleotide primers, the strands are separated by denaturation prior to hybridization with the circular templates. Heat or alkaline denaturation are two common procedures for the separation of nucleic acid strands but a variety of other methods are known to one skilled in the art which can also be used. Detection of the analyte in the form of intermediary displacement products or in the form of linear complements can be performed using standard fluorescent staining or hybridization techniques known to one skilled in the art. The invention also provides a process for detecting multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site by the steps of: (a) combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization; b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template ; (c) cleaving the displacement product to generate linear complements of the circle template; (d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization; (e) repeating steps (b) through (d) at least once to generate linear complements of the circle template; and (g) detecting the linear complements.
The invention further provides products such as DNA,
RNA, polypeptides and antibodies produced from either the displacement products, displacement products hybridized to restriction polynucleotides, linear complements or linear complements hybridized to restriction polynucleotides. These nucleic acids products, or nucleic acids encoding these products, can be cloned into a vector for propagation in either encaryotic or procaryotic organisms using ordinary skills in the art. The choice of the vector will depend on the organism in which the nucleic acid will be propagated. Additionally, the cloned products can be expressed in vivo for polypeptide production (using expression vectors) or they can be transcribed and (using transcription vectors) and translated in vitro to produce recombinant polypeptides. Such recombinant polypeptides derived by in vivo or in vitro methods can further be used to generate monoclonal or polyclonal antibodies as described by Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, which is incorporated herein by reference.
The following examples are intended to illustrate but not limit the invention.
EXftffPEE?
Circular M13mpl8DNA (single or double stranded) was purchased from U.S. Biochemical (Cleveland, OH). All synthetic oligonucleotides were made using standard phosphoramidite chemistry on an Applied Biosysterns 380A DNA synthesizer (Applied Biosystems, Foster City CA). Purifications of DMT-on oligonucleotides was by "DMTon" reverse phase HPLC using 0.3 x 15 cm C-8 (3μ) columns eluting 5 to 30% acetonitrile in 100 mM triethyl-ammonium acetate at 1.0 ml/min. Phosphoramidites of 5-methyl-2' deoxycytidine and 5»- phosphorylating reagent were purchased from Glen Research, Herdon, VA. Where indicated, oligonucleotide linkers are synthesized with a blocked 3'- end by synthesis on Branched Modifier Icaa-CPG (Glen Research) , which results in oligomers with alkylamines on the 3'-hydroxyl. Size estimation of circles and extension products were based on mobility by agarose (0.5-4%) or polyacrylamide (4-20%) gel electrophoresis; size markers were either Hae III restricted double-stranded Phixl74 or Hae Ill-restricted single-stranded M13 DNA. Total nucleic acid synthesis was quantitated by ionic adsorption of nucleic acid onto DE-81 disks after incorporation of KP- dATP or ^P-dCTP using the method as described in Molecular Cloninα: A Laboratory Manual, volume 3, 1988 Sambrook et al, eds, p. E18-E19. The number of primers extended in a reaction was quantitated by using MP-end labeled primers of known specific activity.
The average number of complements produced from a 26 primed single stranded DNA circle was determined as follows: the circular single stranded DNA is primed by addition of a ten fold molar excess of complementary primer. A primer extension reaction was carried out on the bound primer in the presence of alpha-32P-dATP of known specific activity. The total amount of 32P incorporated into circle complement was measured by spotting 2-5 μL of the reaction mixture onto Whatman DE81 ion exchange paper. The DE81 paper was washed five times in 0.3M NaP04 pH 7.0 for 5 minutes per wash to remove unincorporated 32P-dATP. The DE81 paper was counted by scintillation counting. The number of adenosine residues per circle complement and the circle concentration was known; allowing calculation of specific activity per circle complement and the number of circle complements produced per circle.
EXAMPLE I
Extension of a 7300 Base Pair M13 Sinole-Stranded Circle to Produce Multiple Copies
This example illustrates the ability of DNA polymerases to displace complement strands produced after extension and the ability of polymerases to incorporate several hundred bases per minute.
A 19 μl reaction volume contained 50 nM M13 model primer (sequence: 5'-dGGTTTTCCCAGTCACGACG) and 5 nM M13mpl8 single-stranded circular DNA (U.S. Biochemical, Cleveland, OH) in Extension Buffer (10 mM Tris, pH 7.4, 10 mM MgCl, 1 mM dithiothreitol (DTT)) containing 200 μM dGTP, dCTP, dTTP, and alpha-^P-dATP (6 μCi/μmol) . The extension was initiated by addition of 1 μl containing 2 units of DNA polymerase Klenow fragment (BRL, Gaithersburg, MD) . Negative controls consisted of either no primer added or no enzyme added. The extension was incubated for one hour at either 37* or 50*C. Total DNA synthesis was determined by spotting 2 μl aliquots on DE81 anion exchange paper disks (Whatman, Clifton, NJ) , and washed three times in 0.5 M sodium phosphate, pH 7.3. Aliquots of 2-5 μl were also analyzed by agarose gel electrophoresis followed by autoradiography on XAR film (Kodak, Rochester, NY) to estimate average size of fragments produced by the extension. The results indicated that the average size of circle complement produced was greater than 25,000 bases, or an extension rate of more than 417 bases per minute. This represents more than 18,000 bases of displacement.
EXAMPLE II Construction of a 682-Base single-Stranded Circle Based on M13
This example illustrates the construction of a medium size single-stranded circle using recombinant enzymatic methods.
One milligram of single-stranded M13mpl8 (U.S. Biochemical, Cleveland, OH) was ethanol precipitated from 1500 μl total volume containing 300 mM sodium acetate, pH 5.4, and pelleted by centrifugation. The supernatent was removed, and the pellet washed with 70% ethanol and dried under vacuum. The DNA was redissolved in 500 μl water. A portion of the solution (90 μl, 180 μg of DNA « 76 pmols) was treated in the following manner: 1.5 μl (750 pmols) of each of two restriction site oligonucleotides were added (500 μM Bgl II/M13 restriction site oligonucleotide sequence: 5»-dTGAGAGATCTACAAAGGCTATCAGGTCATTGCCT; AND 10 μM Bam Hi/Ml3 restriction oligonucleotide, sequence 5'- dTGCATGCCTGCAGGTCGACTCTAGAGGATCCCCG) ; 15 μl of 10X Universal buffer (Stratagene Cloning Systems, La Jolla, CA) plus 27 μl H20 was added. The mixture was heated to 65*C for 3 minutes, then cooled on ice for 5 minutes. 7.5 μl of Bam HI restriction endonuclease (Boehringer Mannheim, Indianapolis, IN) and 7.5 μl of Bgl II restriction endonuclease (Boehringer Mannheim, Indianapolis, IN) was added and the mixture was incubated at 37*C for three hours. 28
After incubation, the digest was checked for completion on a 1.5% agarose mini-gel with approximately 0.5 μg of the digested DNA. A preparative 1.5% agarose (FMC SeaKe GTG, Rockland, ME)/TAE was prepared with marker lanes. Agarose gel loading dyes (15.0 μl) were added to the digest. Ten μl of this preparation were loaded in the marker lane and the remainder in the preparative well. The sample was electrophoresed in TAE buffer for 1.5 hours at 25 mA.
The marker lane was cut from the gel and stained with ethidium bromide in water at a concentration of 0.5 μg/ l. The 682 bp fragment was located under UV light and then excised from the corresponding location on the gel.
The gel slice was loaded onto a Schleicher & Schuell Elutrap (Schleicher & Schuell, Keene, NH) and electroeluted in lx TAE buffer for 4 hours at 130 V. The eluate was recovered and butanol extracted 4 times,
Phenol/chloroform/isoamyl alcohol extracted twice and chloroform/isoamyl alcohol extracted one time. One tenth volume of 3 M sodium acetate pH 5.4 and 2.5 volumes of 100% ethanol were added and the preparation was incubated in an ethanol/dry ice bath for 20 minutes. The preparation was then centrifuged in a microfuge for 30 minutes at room temperature at 14,000 X G. The supernate was discarded, 0.75 ml of 70% ethanol was added to wash the pellet and the preparation was then re-centrifuged for 5 minutes under the same conditions. Ethanol was removed and the pellet was dried under vacuum for 3 minutes.
The dried pellet was redissolved in 100 μl of H20 and loaded onto a Centricon 100 (Amicon, Danvers, ME). Two mis of 50 mM NaOH/1 mM EDTA were added and the preparation was spun in a fixed angle rotor, (Model SS34; Dupont-Sorvall,
Wilmington, DE) centrifuged for 45 minutes at room temperature at 2400 rpm. The above steps were repeated with an additional two mis of NaOH/EDTA. One ml of TE 10:1 pH 8.0 (10 mM Tris pH 8.0, 1 mM EDTA) was added and centrifuged as above.
Circularization of the 682 bp fragment was performed as follows: The retentate was recovered from Centricon 100 filter apparatus at a total volume of 38 μl. Forty μl of 5X ligase buffer (BRL, Gaithersburg, MD) were added. A linker molecule to span both ends of the linear 682 bp fragment was synthesized as described above. The synthesized linker molecule, designated M13/682 ligation linker, had the following sequence: β'dCGACTCTAGAGGATCTACAAAGGCTATCAGCAA. One hundred and seven μl of H20 were added and the preparation was incubated at 65*c for 5 minutes, followed by flash cooling on ice for 5 minutes. Three μl of T4 DNA Ligase (BRL, Gaithersburg, MD) containing lU/μl were added and the preparation was incubated at 16*C for 1 hour. Following incubation, two additional μls of linker were added. The preparation was incubated at 65*C for 5 minutes, cooled on ice 5 minutes, and then three μls of ligase were added followed by a 1 hour incubation at 16*C. Two additional μls of linker were added, followed by another 65*C incubation, rapid cooling on ice for 5 minutes. Three more μls of ligase were added and reaction was incubated at 16*C overnight.
EXAMPLE III
Construction of a Synthetic ^--Base Single-Stranded Circle with Pr.cected Restriction Sites and a Single Core Secruence
This example illustrates the construction of a small single-stranded circle using oligonucleotide synthesis followed by enzymatic ligation to form the circle.
A 72 base DNA oligomer with a 5'-phosphate ( sequence:
5 -p-d CTTTCACGTTTATCATCTGACTATCCTGTAATAAAGATCAATGCGT"C"C GGTCTACATAGTCTCTAAAATTAG) was synthesized on an Applied Biosystems 380A DNA synthesizer (Applied Biosystems, Foster City, CA) using standard phosphoramidite chemistry. Both deoxycytidines in the Hpall restriction site (CCGG) contained within the 72 base DNA oligomer were replaced with 5-methyldeoxycytidine to prevent cleavage of the oligomer by Hpa II. A 33 base linker sequence that has 15 bases complementary to each end of the 72 base oligomer was also synthesized. The 3' end of the linker has 3 noncomplementary bases and a blocked 3* end to prevent the linker from extending in a polymerase reaction. This oligomer was used to bring the 5' and 31 ends of the 72 base oligomer together to allow for enzymatic ligation.
The 72 base oligomer was enzymatically ligated in a lmL reaction volume containing lOuM of 72 base oligomer, 5uM of 33 base linker oligomer, 40mM Tris-Cl pH 7.5, lOmM MgCl2, lOmM dithiothreotol, and ImM ATP. The reaction mixture was incubated for 5 minutes at 50°C then cooled to room temperature. 40,000 units of T4 DNA Ligase (New England Biolabs, Beverly, MA) was added to the reaction mixture. The reaction mixture was incubated for 2 hours at room temperature. The linker concentration was brought to lOuM and the reaction mixture was incubated an additional 16 hours at room temperature. The linker concentration was increased to 15uM and the reaction mixture was incubated an additional 2 hours at room temperature. The reaction mixture was electrophoresed at 1000V for 4 hours in a 10% polyacylamide/8M urea gel in lxTBE. The slower migrating circular 72mer product was identified by UV shadowing, electroeluted, ethanol precipitated and quantitated by optical density at 260nm. The circular 72mer was resistant to degradation by Exo VII, and could be primer extended past the ligation site. EXAMPLE IV
Construction of a £ nthetic 101-Base
Single-Stranded Circle with Protected
Restriction Sites and a Single Core Seouence
A synthetic lOlmer oligomer (sequence: 5*- pdGATTAAAATCTCTGACCCGAGCCGATGACTTACTGGCwCG',CGTT"CGAA''c"CGGA AΛflOTCCCTGGAGTGCGATCTTCCTGAGGCCGATCTGATAGGACATTAT) was synthesized as in Example III. The underlined portion designates the sequence which is complementary to the 33 base linker described below. The lOlmer oligomer contained blocked restriction sites for the restriction endonucleases Hpa II (CCGG) , Bst Bl (TTCGAA) , and Bst Ul (CGCG) . All the deoxycytosines in the restriction sites of these restriction endonucleases were replaced with 5- methyldeoxycytosines to prevent restriction cleavage. A 33 b a s e l i n k e r ( s e q u e n c e : 5 • - dTCAGAGATTTTAATCATAATGTCCTATCAGTAG) that has 15 bases complementary to each end of the 101 base oligomer was also synthesized. The 3' end of the linker has 3 noncomplementary bases and a 3' amine to prevent the linker from extending in a polymerase reaction. This oligomer was used to bring the 5' and 3* ends of the 101 base oligomer together to allow for enzymatic ligation. The 101 base oligomer was enzymatically ligated and purified as in Example III. The circular lOlmer was resistant to degradation by Exo VII and could be primer extended past the site of ligation.
EXAMPLE V
Construction of a Synthetic 202-Base Single-Stranded Circle with Protected
Restriction Sites and a Repeated Core Seouence
This example illustrates the construction of a small single-stranded circle composed of two core sequences with unique ends enzymatically ligated to form the circle.
A synthetic 101 base oligomer (sequence: 5'- 32 pdTTCTAGTTACGCAGGCCCGAGCCGATGACTTACTGGCCGCGTTCGAACCGGAAAG rτnrC!TGGAGTGCGATCTTCCTGAGGCCGATACTATTTGCACTTTC) was synthesized as in Example III with the same 71 base core sequence but with different 15 base linker sequences on each end of the 101 base oligomer. The different linker sequences, which are underlined, allow for specific ligation between the 101 base oligomer shown above and the 101 base oligomer from Example IV. Two 34 base linkers (sequences: (1) 5'-dCCTGCGTAACTAGAAATAATGTCCTATCAGTTTT- NH2 and (2) 5'-dTCAGAGATTTTAATCGAAAGTGCAAATAGTCCCC-NH2) that have 15 bases complementary to one end of each 101 base oligomer were also synthesized. The 3* end of the linkers have 4 noncomplementary bases and a 3• amine to prevent the linkers from extending in a polymerase reaction. Each linker wwas used to bring the 5' end of one 101 base oligomer and 3' end of the other 101 base oligomer together to allow for enzymatic ligation.
The 101 base oligomers were enzymatically ligated and purified into a 202 base oligomer as in Example III except that each 101 base oligomer was at 0.6 μM and the first linker was at 0.15 μM starting concentration and increased to 0.75 μM. The 101 base oligomers were also gel purified before ligation instead of after ligation. The 202 base oligomer was then ligated into a circle as in Example III except the 202 base oligomer was at 0.3 μM and the second linker was at 0.15 μM starting concentration and increased to 1.2 μM.
EXAMPLE VI Extension of a 682-Base Single-Stranded Circle
This example illustrates the ability of DNA polymerases to displace complement strands produced after extension, and the ability of polymerases to incorporate several hundred bases per minute into a medium-sized single-stranded circle. A primer extension reaction was carried out and extension products determined as described in Example I. Extension reactions for the circular 682 bp single strand, nucleic acid were performed using free nucleotides, a DNA Polymerase (BRL, Gaithersburg, MD) , a synthetic KP labeled primer fragment (5000 cp /fmole) and T4 Polynucleotide Kinase (New England Biolabs, Beverly, MA ) . T h e p r i m e r s e q u e n c e w a s 5'TGAACGGTAATCGTAAAACTAGCATGTCAATCATATGTACCCCGGTTGAT3•. Reactions were performed in 20 μl volumes with a 10:1 molar ratio of primer to circle, dithiothreotol (DTT) at a final concentration of 5 mM, free dNTP's (Pharmacia, Pleasant Hill, CA) at a final concentration of 200 μM, Klenow DNA polymerase (Boehringer Mannheim, Indianapolis, IN) , and 10X extension buffer. Reactions were incubated at 37*C for one hour. Three and a half μls of 6X alkaline gel loading buffer were added to the reactions and then electrophoresis was carried out in a 0.7% alkaline agarose gel for 16 hours at 150 mA. The gel was neutralized and stained as described above and then exposed on Kodak X-OMAT AR film (Kodak, Rochester, NY) at room temperature with a screen for two hours to analyze extension products. The average size of circle complement produced using a 682-base single- stranded circle was greater than 20,000 bases.
EXAMPLE VII Extension of a 72-Base Circle
A primer extension reaction was carried out as in Example I except a different primer was used (sequence: 5•-dACAAGGACCAAAAGAACCTTTTAGAGACTATGTAGAC) . The 19 bases on the 3' end are complementary to the 72 base circle but the 18 bases on the 5* end are not complementary to the circle. The average size of circle complement produced using a 72-base single-stranded circle was 150 to 250 bases. EXAMPLE VIII
Extension of a 7300-Base Single-Stranded Circle, and Restriction to Form Secondary Primers
This example illustrates the ability of Sau 3A endonuclease to restrict the amplified product of a 7300- base single-stranded circle to generate linear complements for use as secondary primers in the next cycle of extension reaction.
A 19 μl reaction volume contained 50 nM M13mpl8 single-stranded circle (U.S. Biochemical, Cleveland, OH) and 5 nM M13 primer (100 fmole) in extension buffer (20 mM Tris pH 7.5, 10 mM MgCl2, 25 mM NaCl, 6.5 mM DTT) containing 200 μM dGTP, dCTP, dATP, dTTP and 0.33 μM of alpha ^P- dATP. The final specific activity of ^P-dATP was 9,000 cpm/pmole. The extension was initiated by addition of 1 μl of DNA polymerase Klenow fragment (BRL, Gaithersburg, MD, 6 units/μl) for 1 hour at 50*C. 2 μl of 8 units/μl Sau3A I enzyme (BRL, Gaithersburg, MD) were added to the 20 μl reaction mix and allowed to digest for 1 hour at 37'C. 4 μl of the 20 μl reaction mix was transferred into a new tube and denatured for 2 minutes at 100*C in a heat block (silicon oil/sand or boiling water) , followed by chilling in a dry ice bath for 1 minute. 16 μl of new reaction mix containing 40 nM M13mpl8 single-stranded circle and the same concentration of extension buffer mentioned above was added to the 4 μl chilled sample. 1 μl of DNA polymerase Klenow fragment was added and the extension reaction was carried out for 1 hour at 50*C. The restriction/denaturation/extension cycles were repeated two more times. The restricted and extended products were analyzed by gel and total DNA synthesis. 2 μl of each sample tube was loaded onto a 0.5% alkaline agarose denaturing gel and run for overnight at 150 mA. A 1:10 diluted stock of each sample tube was prepared and 2 μl was used to spot onto DE81 Whatman paper, washed 3 times in 35
0.5M sodium phosphate, pH 7.3 and counted in a scintillation counter for total count analysis. Denatured, extended samples were used as controls. Results indicated that the extended product was restricted and the restricted fragments in turn acted as primers for the next round of extension. Since each molecule of Ml3mpl8, (complement contains about 1760 adenine residues, incorporation of 9,000cpm/pmol 32p-dATP will result in complement product with specific activity of 16,000 cpm/fmol. Results (E=extension; R=restriction; D=heat denaturation)
Figure imgf000037_0001
These results indicate that 1,375 molecules of circle complement are formed for every original molecule of polynucleotide primer, or a 1,375 fold amplification over original target polynucleotide. Repeating the reaction under isothermal conditions at 50*C gave similar results.
EXAMPLE IX
Extension of a 72-Base Single-Stranded circle, and Restriction to Form Secondary Primers
A primer extension reaction was carried out as in Example VII except Taq DNA Polymerase (Cetus, Emeryville, CA) was used at 60'C instead o: Klenow at 37*C. The extended product was brought to 5 mM in DTT and 1 μM in a 38 base restriction linker (sequence: 5'- dTGACTATCCTGTAATAAAGATCAATGCGTCCGGTCTAC-NH2) . The restriction linker is complementary to the circle complement and renders it double-stranded. 10 units of Hpa II restriction endonuclease were added and the reaction mix was incubated 30 minutes at 37*C. The product was visualized by autoradiography. The circle complement was cleaved into 72 base fragments following this procedure.
Although the invention has been described with references to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

Claims

37WE CLAIM:
1. A process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site comprising:
(a) combining the single strand, circular nucleic acid template with polynucleotide primers underconditions sufficient for hybridization; and
(b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template.
2. A process for generating multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site comprising:
(a) combining the single strand, circular nucleic acid template with polynucleotide primer under conditions sufficient for hybridization;
(b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template;
(c) cleaving the displacement product to generate linear complements of the circle template;
(d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization; and
(e) repeating steps (b) through (d) at least once to generate linear complements of the circle template wherein the last repeated cycle ends at step (b) or (c).
3. The process of claim 2, wherein the circular template of step (a) is denatured prior to use in step (d) .
4. The process of claim 2, wherein the product of step (c) is denatured prior to use in step (d) .
5. The process of claim 1 or 2, wherein all steps are carried out under isothermal conditions.
6. The process of claim 1 or 2, wherein the polynucleotide primers comprise double-stranded nucleic acids, single-stranded nucleic acids or a mixture thereof.
7. The process of claim 6, wherein the nucleic acids are derived from a biological sample.
8. The process of claim 6, wherein the polynucleotide primers are double-stranded and their strands are separated by denaturing before or during step (a).
9. The process of claim 8, wherein the denaturing is thermal.
10. The process of claim 1 or 2, wherein the polynucleotide primers are synthetic oligonucleotides.
11. The process of claim 1 2 , wherein the polynucleotide primers are selected so at o allow strand displacement synthesis by a polymerase.
12. The process of claim 1 or 2, wherein the 5' end of the polynucleotide primers are non-complementary to the circular template.
13. The process of claim 1 or 2, wherein the 5' end of the nucleotide primers are blocked.
14. A process of synthesizing a single strand, circular nucleic acid comprising:
(a) chemically synthesizing a linear polynucleotide;
(b) combining the linear polynucleotide with a complementary linking oligonucleotide under conditions sufficient for hybridization; and
(c) ligating the linear polynucleotide to produce a single strand, circular nucleic acid.
15. The process of claim 14, wherein the circular nucleic acid is synthesized as two or more linear polynucleotides.
16. A single strand, circular nucleic acid, wherein the nucleic acid comprises between 30 and 2200 nucleotides.
17. The single strand, circular nucleic acid of claim 16, wherein the nucleic acid comprises between 30 and 750 nucleotides.
18. The single strand, circular nucleic acid of claim 17, wherein the nucleic acid comprises between 50 and 300 nucleotides.
19. The single strand, circular nucleic acid of claim 18, wherein the circular nucleic acid further comprises at least one cleavage site.
20. The single strand, circular nucleic acid of claim 19, wherein a portion of the circular nucleic acid is complementary to polynucleotide primers derived from a biological sample comprising double-stranded nucleic acids, single-stranded nucleic acids or a mixture thereof.
21. The process of claim 1 or 2, wherein the single strand, circular nucleic acid template is derived from phage replication.
22. The process of claim 1 or 2, wherein the single strand, circular nucleic acid template is between 50 and 2200 nucleotides.
23. The process of claim 1 or 2, wherein the single strand, circular nucleic acid template is made from chemically synthesized oligo- or poly-nucleotides.
24. The process of claim 23, wherein the single strand, circular nucleic acid template is between 50 and 750 nucleotides.
25. The process of claim 1 or 2, wherein the cleaving of the displacement product is achieved by one or more restriction endonucleases.
26. The process of claim 25, wherein the one or more restriction endonuclease sites on the single strand, circular nucleic acid template are capable of be ing modified so as to inhibit restriction of
Figure imgf000043_0001
least the modified strand.
27. The process of claim 25, wherein the restriction endonuclease site is Hpa II.
28. The process of claim 26, wherein the one or more restriction endonuclease sites are modified by methylation.
29. The process of claim 1 or 2, wherein the restriction polynucleotides are selected so that when restricted, a fragment of the restriction polynucleotide remains hybridized to the 5' end of the displacement product.
30. The process of claim 1 or 2, wherein the restriction polynucleotides are deoxyribonucleic acids and the 3' end is inhibitory to primer extension by a polymerase.
31. The process of claim 1 or 2, wherein the polymerase is selected from the group comprising E. coli DNA polymerase I, Klenow fragment, T4 DNA polymerase, T7 DNA polymerase, modified polymerases, reverse transcriptase, Taq polymerase, Bst polymerases or T. flavins polymerase.
32. A process for detecting multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site comprising:
(a) combining the single strand, circular nucleic acid template with polynucleotide primers under conditions sufficient for hybridization;
(b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template;
(c) detecting the linear complements.
44
33. A process for detecting multiple linear complements of a single strand, circular nucleic acid template containing at least one cleavage site comprising:
(a) combining the single strand, circular nucleic acid template with polynucleotideprimers underconditions sufficient for hybridization;
(b) extending the polynucleotide primer more than once around the circle to generate a complementary displacement product comprising more than one contiguous complement of the single strand, circular nucleic acid template;
(c) cleaving the displacement product to generate linear complements of the circle template;
(d) combining the single strand, circular template of step (a) with the linear complements produced in step (c) under conditions sufficient for hybridization;
(e) repeating steps (b) through (d) at least once to generate linear complements of the circle template, wherein the last repeated step ends at step (b) or (c) ; and
(f) detecting the linear complements.
34. The process of claim 32 or 33, wherein the detecting step is by hybridization.
35. The process of claim 32 or 33, wherein the detecting step is by fluorescence.
36. The process of claim 32 or 33, wherein the polynucleotide primers comprise double-stranded nucleic acids, single-stranded nucleic acids or a mixture thereof.
37. The process of claim 36, wherein the nucleic acids are derived from a biological sample.
38. The displacement products produced by the process of claim 1 or 2.
39. The displacement products hybridized to the restriction polynucleotides produced by the process of claim 1 or 2.
40. The linear complements produced by the process of claim 1 or 2.
41. A product made with the product of claim 38 selected from the group consisting of DNA, RNA, polypeptide and antibody.
42. A product made with the product of claim 39 selected from the group consisting of DNA, RNA, polypeptide and antibody.
43. A product made with the product of claim 40 selected from the group consisting of DNA, RNA, polypeptide and antibody.
44. The process of claim 1 further comprising step (c) cleaving of the displacement product to generate linear complements of the circle template.
45. The process of claim 1 or 2, wherein the polynucleotide primers are affinity selected.
PCT/US1991/005067 1990-07-25 1991-07-17 Circular extension for generating multiple nucleic acid complements WO1992001813A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU84173/91A AU649066B2 (en) 1990-07-25 1991-07-17 Circular extension for generating multiple nucleic acid complements
CA002087256A CA2087256A1 (en) 1990-07-25 1991-07-17 Circular extension for generating multiple nucleic acid complements
NO930235A NO930235D0 (en) 1990-07-25 1993-01-22 RING EXTENSION FOR MULTIPLE NUCLEIC ACID COMPLEMENTATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55864590A 1990-07-25 1990-07-25
US558,645 1990-07-25

Publications (1)

Publication Number Publication Date
WO1992001813A1 true WO1992001813A1 (en) 1992-02-06

Family

ID=24230368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005067 WO1992001813A1 (en) 1990-07-25 1991-07-17 Circular extension for generating multiple nucleic acid complements

Country Status (5)

Country Link
EP (1) EP0542874A4 (en)
JP (1) JPH06500014A (en)
AU (1) AU649066B2 (en)
CA (1) CA2087256A1 (en)
WO (1) WO1992001813A1 (en)

Cited By (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502180A1 (en) * 1990-09-21 1992-09-09 Amgen Inc Enzymatic synthesis of oligonucleotides.
EP0684315A1 (en) * 1994-04-18 1995-11-29 Becton, Dickinson and Company Strand displacement amplification using thermophilic enzymes
US5645987A (en) * 1990-09-21 1997-07-08 Amgen Inc. Enzymatic synthesis of oligonucleotides
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
WO1997042346A1 (en) * 1996-05-02 1997-11-13 Tepnel Medical Limited Amplification of nucleic acids
EP0812911A2 (en) * 1996-06-10 1997-12-17 Japan Science and Technology Corporation A method of forming a macromolecular microgene polymer
WO1998027225A1 (en) * 1996-12-16 1998-06-25 Cytocell Limited Assay involving looped nucleic acid
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO1999009216A2 (en) * 1997-08-13 1999-02-25 University Of Rochester Highly sensitive multimeric nucleic acid probes
WO1999049079A1 (en) * 1998-03-25 1999-09-30 Ulf Landegren Rolling circle replication of padlock probes
AU714486B2 (en) * 1995-11-21 2000-01-06 Yale University Unimolecular segment amplification and detection
WO2000015849A1 (en) * 1998-09-15 2000-03-23 Yale University Artificial long terminal repeat vectors
WO2000015779A2 (en) * 1998-09-15 2000-03-23 Yale University Molecular cloning using rolling circle amplification
WO2000022163A2 (en) * 1998-10-12 2000-04-20 Attomol Gmbh Molekulare Diagnostika Method and kit for directly detecting nucleotide sequences, amino acid sequences or antigens
WO2000023619A1 (en) * 1998-10-20 2000-04-27 Tepnel Medical Limited Template chain reaction
US6096880A (en) * 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US6221603B1 (en) * 2000-02-04 2001-04-24 Molecular Dynamics, Inc. Rolling circle amplification assay for nucleic acid analysis
WO2001029079A1 (en) 1999-10-18 2001-04-26 Prince Henry's Institute Of Medical Research IMMUNO-INTERACTIVE FRAGMENTS OF THE αC SUBUNIT OF INHIBIN
WO2001040516A2 (en) * 1999-12-02 2001-06-07 Molecular Staging Inc. Generation of single-strand circular dna from linear self-annealing segments
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
WO2001059101A1 (en) * 2000-02-10 2001-08-16 The Penn State Research Foundation Method for amplifying full length single strand polynucleotide sequences
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6316229B1 (en) 1998-07-20 2001-11-13 Yale University Single molecule analysis target-mediated ligation of bipartite primers
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
WO2002024219A1 (en) 2000-09-22 2002-03-28 Queensland University Of Technology Growth factor complex
US6448017B1 (en) 1992-08-04 2002-09-10 Replicon, Inc. In vitro amplification of nucleic acid molecules via circular replicons
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
EP1300466A2 (en) * 1995-12-05 2003-04-09 Jorn Erland Koch A cascade nucleic acid amplification reaction
US6573051B2 (en) 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US6686157B2 (en) 2000-06-30 2004-02-03 Molecular Staging Inc. Signal amplification with lollipop probes
JP2004511221A (en) * 2000-07-21 2004-04-15 インサイト ジェノミクス インコーポレイテッド Computer readable media incorporating computer readable programs for nucleic acid sequence isolation methods, high throughput methods for determining nucleic acid sequences of large numbers of nucleic acids based on known nucleic acid sequences, and methods for determining nucleic acid sequences
WO2004099403A1 (en) 2003-05-12 2004-11-18 The University Of Queensland A method of increasing the total or soluble carbohydrate content or sweetness of an endogenous carbohydrate by catalysing the conversion of an endogenous sugar to an alien sugar.
US6830884B1 (en) 1998-12-15 2004-12-14 Molecular Staging Inc. Method of amplification
WO2005108608A1 (en) * 2004-05-10 2005-11-17 Kabushiki Kaisha Dnaform Method for isolating nucleic acid isoforms
WO2006063415A1 (en) 2004-12-17 2006-06-22 Monash University Regulation of metalloprotease cleavage of cell surface proteins
WO2006095169A1 (en) * 2005-03-08 2006-09-14 Lingvitae As Method for preparing polynucleotides for analysis
US7135312B2 (en) 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
EP1833994A2 (en) * 2005-01-04 2007-09-19 Hitachi Chemical Co., Ltd. Primer generation rolling circle amplification
WO2008144827A1 (en) 2007-05-31 2008-12-04 The University Of Queensland Diagnostic markers for ankylosing spondylitis and uses thereof
US20090011943A1 (en) * 2005-06-15 2009-01-08 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US7501254B2 (en) 2006-07-20 2009-03-10 Ghc Technologies, Inc. Methods and compositions for amplification and capture of nucleic acid sequences
EP2058396A1 (en) * 2006-08-31 2009-05-13 Toyo Seikan Kaisha, Ltd. Nucleic acid amplification method
US7838270B2 (en) 2001-05-22 2010-11-23 The University Of Chicago Target-dependent transcription using deletion mutants of N4 RNA polymerase
EP2267117A2 (en) 2002-06-27 2010-12-29 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
EP2316959A2 (en) 2001-04-18 2011-05-04 Gene Stream Pty Ltd. Transgenic non-human animals for pharmacological and toxicological studies
WO2011063477A1 (en) 2009-11-30 2011-06-03 Queensland University Of Technology Fibronectin: growth factor chimeras
US7960104B2 (en) * 2005-10-07 2011-06-14 Callida Genomics, Inc. Self-assembled single molecule arrays and uses thereof
US7989166B2 (en) 2005-04-12 2011-08-02 In Situ Rcp A/S Circle probes and their use in the identification of biomolecules
EP2357195A1 (en) 2003-02-05 2011-08-17 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US8080393B2 (en) 2005-04-12 2011-12-20 Olink Ab Methods for production of oligonucleotides
US8093030B2 (en) 2005-10-06 2012-01-10 Lucigen Corporation Thermostable viral polymerases and methods of use
US8323929B2 (en) 1999-06-17 2012-12-04 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9090706B2 (en) 2003-02-05 2015-07-28 Queensland University Of Technology Fibronectin: growth factor chimeras
US9109250B2 (en) 2009-01-30 2015-08-18 Vanessa Hill Production of closed linear DNA
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9228228B2 (en) 2006-10-27 2016-01-05 Complete Genomics, Inc. Efficient arrays of amplified polynucleotides
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US9499847B2 (en) 2010-08-04 2016-11-22 Touchlight IP Limited Production of closed linear DNA using a palindromic sequence
EP2970961A4 (en) * 2013-03-15 2016-12-21 Theranos Inc Nucleic acid amplification
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9551027B2 (en) 2013-03-15 2017-01-24 Theranos, Inc. Nucleic acid amplification
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9683255B2 (en) 2005-09-09 2017-06-20 Qiagen Gmbh Method for activating a nucleic acid for a polymerase reaction
US9916428B2 (en) 2013-09-06 2018-03-13 Theranos Ip Company, Llc Systems and methods for detecting infectious diseases
US9944984B2 (en) 2005-06-15 2018-04-17 Complete Genomics, Inc. High density DNA array
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US10174366B2 (en) 2012-11-14 2019-01-08 Olink Bioscience Ab Localised RCA-based amplification method
EP3424524A2 (en) 2017-07-04 2019-01-09 CureVac AG Cancer rna-vaccine
US10227632B2 (en) 2013-11-29 2019-03-12 Q-Linea Ab Rolling circle amplification method
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
US10450595B2 (en) 2013-03-15 2019-10-22 Theranos Ip Company, Llc Nucleic acid amplification
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
WO2020180751A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Compositions, methods, and kits for delivery of polyribonucleotides
WO2020181013A1 (en) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
WO2020180752A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
WO2020198403A2 (en) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
WO2020257727A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
WO2020257730A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
US10953033B2 (en) 2017-12-15 2021-03-23 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
WO2021155175A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
WO2021236930A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2021236980A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Coronavirus antigen compositions and their uses
US11254960B2 (en) 2013-03-15 2022-02-22 Labrador Diagnostics Llc Nucleic acid amplification
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2022066757A1 (en) 2020-09-23 2022-03-31 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells
US11649486B2 (en) 2016-08-16 2023-05-16 Navinci Diagnostics Ab Double-stranded circle probes
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023115013A1 (en) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
US11739389B2 (en) 2017-05-17 2023-08-29 Microbio Pty Ltd Biomarkers and uses thereof
US11918605B1 (en) 2015-02-19 2024-03-05 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
US11944680B2 (en) 2020-11-04 2024-04-02 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6486874A (en) * 1987-09-29 1989-03-31 Sanwa Kagaku Kenkyusho Co Cloned dna containing transcription promoting factor s-ii, its fragment, preparation thereof, plasmid containing said cloned dna or fragment and method for diagnosing viral disease and cancer using said cloned dna or fragment
GB8808892D0 (en) * 1988-04-15 1988-05-18 British Bio Technology Gene synthesis
US4994370A (en) * 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5001050A (en) * 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5071743A (en) * 1989-10-27 1991-12-10 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Process for conducting site-directed mutagenesis

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
°BIOSIS, 1979; no. 69057578/ *
°BIOSIS, 1980; no. 70030184/ *
°BIOSIS, 1985; no. 80067350/ *
°WATSON, "Molecular Biology of the GENE", 3rd ed., N.W. Benjamin Inc. (Publ.); pp. 238-341/ *
Biosis Abstract No. 69057578, issued 1979, "Bacteria Phage .... Microscopy", see Abstract J. Mol. Biol. 105(1) 69-90, KEEGSTRA et al., see the Abstract. *
Biosis Abstract No. 70030184, issued 1980, "The Rolling Circle ....Assembly", see Abstract, KOTHS et al., J. Biol. Chem. 255(9), 4328-4338. *
Biosis Abstract No. 80067350, issued 1985, "The complete 30-Base-Pair ...Packaging", see Abstract, Eur. J. Biochem. 149(3), 579-584, FLUIT et al. *
Journal of Bacteriology, Vol. 171, No. 6, issued June 1989, SHAVITT et al., "Rolling-Circlee Replication of UV-Irradiated Duplex DNA in the X174 Replicative-Form Single-Strand System in Vitro", pages 3530-3533, see entire document. *
Medline, Abstract No. 87137459, issued 1987, MOK et al., "Formulation of rolling circle....replication", see Abstract, J. Biol. Chem., 262(5), 2304-2309. *
Nucleic Acids Research, Vol. 18, No. 9, issued 24 May 1990, CAPOBIANCO et al., "One pot solution synthesis of cyclic oligonucleotides", pages 2661-2669, see "Cyclization reaction". *
See also references of EP0542874A4 *
WATSON, "Molecular Biology of the Gene", 3rd ed., published N.W. Benjamin, Inc., pages 238-241, see entire document. *

Cited By (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863732A (en) * 1990-09-21 1999-01-26 Amgen Inc. Diagnostic kits for detection of target nucleic acid sequences
EP0502180A4 (en) * 1990-09-21 1993-03-17 Amgen Inc. Enzymatic synthesis of oligonucleotides
EP0502180A1 (en) * 1990-09-21 1992-09-09 Amgen Inc Enzymatic synthesis of oligonucleotides.
US5645987A (en) * 1990-09-21 1997-07-08 Amgen Inc. Enzymatic synthesis of oligonucleotides
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US5872105A (en) * 1991-03-27 1999-02-16 Research Corporation Technologies Inc. Single-stranded circular oligonucleotides useful for drug delivery
US6740745B2 (en) 1992-08-04 2004-05-25 Replicon, Inc. In vitro amplification of nucleic acid molecules via circular replicons
US6448017B1 (en) 1992-08-04 2002-09-10 Replicon, Inc. In vitro amplification of nucleic acid molecules via circular replicons
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
US7906490B2 (en) 1993-04-15 2011-03-15 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US6096880A (en) * 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US7135312B2 (en) 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US6368802B1 (en) 1993-04-15 2002-04-09 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
EP0684315A1 (en) * 1994-04-18 1995-11-29 Becton, Dickinson and Company Strand displacement amplification using thermophilic enzymes
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6329150B1 (en) 1995-11-21 2001-12-11 Yale University Unimolecular segment amplification and sequencing
AU714486B2 (en) * 1995-11-21 2000-01-06 Yale University Unimolecular segment amplification and detection
US6797474B2 (en) 1995-11-21 2004-09-28 Yale University Rolling circle replication reporter systems
US6210884B1 (en) 1995-11-21 2001-04-03 Yale University Rolling circle replication reporter systems
US6143495A (en) * 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US6344329B1 (en) 1995-11-21 2002-02-05 Yale University Rolling circle replication reporter systems
US6183960B1 (en) 1995-11-21 2001-02-06 Yale University Rolling circle replication reporter systems
US6632609B2 (en) 1995-11-21 2003-10-14 Yale University Unimolecular segment amplification and sequencing
EP1300466A3 (en) * 1995-12-05 2004-01-02 Jorn Erland Koch A cascade nucleic acid amplification reaction
US6610481B2 (en) 1995-12-05 2003-08-26 Koch Joern Erland Cascade nucleic acid amplification reaction
EP1300466A2 (en) * 1995-12-05 2003-04-09 Jorn Erland Koch A cascade nucleic acid amplification reaction
WO1997042346A1 (en) * 1996-05-02 1997-11-13 Tepnel Medical Limited Amplification of nucleic acids
EP0812911A3 (en) * 1996-06-10 2001-04-18 Japan Science and Technology Corporation A method of forming a macromolecular microgene polymer
EP0812911A2 (en) * 1996-06-10 1997-12-17 Japan Science and Technology Corporation A method of forming a macromolecular microgene polymer
AU724804B2 (en) * 1996-12-16 2000-09-28 British Biocell International Limited Assay involving looped nucleic acid
WO1998027225A1 (en) * 1996-12-16 1998-06-25 Cytocell Limited Assay involving looped nucleic acid
US6566058B1 (en) 1996-12-16 2003-05-20 British Biocell International Limited Assay involving looped nucleic acid
WO1999009216A3 (en) * 1997-08-13 1999-05-06 Univ Rochester Highly sensitive multimeric nucleic acid probes
WO1999009216A2 (en) * 1997-08-13 1999-02-25 University Of Rochester Highly sensitive multimeric nucleic acid probes
WO1999049079A1 (en) * 1998-03-25 1999-09-30 Ulf Landegren Rolling circle replication of padlock probes
US6316229B1 (en) 1998-07-20 2001-11-13 Yale University Single molecule analysis target-mediated ligation of bipartite primers
WO2000015849A1 (en) * 1998-09-15 2000-03-23 Yale University Artificial long terminal repeat vectors
WO2000015779A3 (en) * 1998-09-15 2000-08-10 Univ Yale Molecular cloning using rolling circle amplification
WO2000015779A2 (en) * 1998-09-15 2000-03-23 Yale University Molecular cloning using rolling circle amplification
US6287824B1 (en) 1998-09-15 2001-09-11 Yale University Molecular cloning using rolling circle amplification
US6255082B1 (en) 1998-09-15 2001-07-03 Yale University Artificial long terminal repeat vectors
WO2000022163A3 (en) * 1998-10-12 2000-08-03 Attomol Gmbh Molekulare Diagno Method and kit for directly detecting nucleotide sequences, amino acid sequences or antigens
WO2000022163A2 (en) * 1998-10-12 2000-04-20 Attomol Gmbh Molekulare Diagnostika Method and kit for directly detecting nucleotide sequences, amino acid sequences or antigens
WO2000023619A1 (en) * 1998-10-20 2000-04-27 Tepnel Medical Limited Template chain reaction
US7358047B2 (en) 1998-12-15 2008-04-15 Qiagen Gmbh Methods of forming circular nucleic acid probes and uses thereof
US6830884B1 (en) 1998-12-15 2004-12-14 Molecular Staging Inc. Method of amplification
US8323929B2 (en) 1999-06-17 2012-12-04 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2001029079A1 (en) 1999-10-18 2001-04-26 Prince Henry's Institute Of Medical Research IMMUNO-INTERACTIVE FRAGMENTS OF THE αC SUBUNIT OF INHIBIN
EP2112159A2 (en) 1999-10-18 2009-10-28 Prince Henry's Institute of Medical Research Immuno-interactive fragments of the alpha C subunit of inhibin
WO2001040516A2 (en) * 1999-12-02 2001-06-07 Molecular Staging Inc. Generation of single-strand circular dna from linear self-annealing segments
WO2001040516A3 (en) * 1999-12-02 2002-07-11 Molecular Staging Inc Generation of single-strand circular dna from linear self-annealing segments
US7041480B2 (en) 1999-12-02 2006-05-09 Qiagen Gmbh Generation of single-strand circular DNA from linear self-annealing segments
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
EP2395013A2 (en) 2000-01-25 2011-12-14 The University of Queensland Proteins comprising conserved regions of Neisseria meningitidis surface antigen NhhA
US6221603B1 (en) * 2000-02-04 2001-04-24 Molecular Dynamics, Inc. Rolling circle amplification assay for nucleic acid analysis
WO2001059101A1 (en) * 2000-02-10 2001-08-16 The Penn State Research Foundation Method for amplifying full length single strand polynucleotide sequences
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6670126B2 (en) * 2000-05-12 2003-12-30 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US6686157B2 (en) 2000-06-30 2004-02-03 Molecular Staging Inc. Signal amplification with lollipop probes
JP2004511221A (en) * 2000-07-21 2004-04-15 インサイト ジェノミクス インコーポレイテッド Computer readable media incorporating computer readable programs for nucleic acid sequence isolation methods, high throughput methods for determining nucleic acid sequences of large numbers of nucleic acids based on known nucleic acid sequences, and methods for determining nucleic acid sequences
EP2385064A2 (en) 2000-09-22 2011-11-09 Queensland University of Technology Agents disrupting a growth factor complex
EP2385063A2 (en) 2000-09-22 2011-11-09 Queensland University of Technology Growth factor complex
WO2002024219A1 (en) 2000-09-22 2002-03-28 Queensland University Of Technology Growth factor complex
US6573051B2 (en) 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
EP2316959A2 (en) 2001-04-18 2011-05-04 Gene Stream Pty Ltd. Transgenic non-human animals for pharmacological and toxicological studies
EP2336338A2 (en) 2001-04-18 2011-06-22 Gene Stream Pty Ltd. Transgenic non-human animals for pharmacological and toxicological studies
US7838270B2 (en) 2001-05-22 2010-11-23 The University Of Chicago Target-dependent transcription using deletion mutants of N4 RNA polymerase
JP4675424B2 (en) * 2001-08-03 2011-04-20 オーリンク エイビー Nucleic acid amplification method
JP2009297045A (en) * 2001-08-03 2009-12-24 Olink Ab Nucleic acid amplification method
JP2009077735A (en) * 2001-08-03 2009-04-16 Biocyclica Ab Nucleic acid amplification method
EP2236622B1 (en) * 2001-08-03 2017-09-06 Olink Bioscience AB Method for generating circularised nucleic acid
US7320860B2 (en) 2001-08-03 2008-01-22 Olink A.B. Nucleic acid amplification method
EP2236622A2 (en) 2001-08-03 2010-10-06 Olink AB Method for generating circularised nucleic acid
USRE44265E1 (en) 2001-08-03 2013-06-04 Olink Ab Nucleic acid amplification method
JP4559517B2 (en) * 2001-08-03 2010-10-06 オーリンク エイビー Nucleic acid amplification method
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
EP2251439A1 (en) 2001-08-03 2010-11-17 Olink AB Nucleic acid amplification method
JP2010183916A (en) * 2001-08-03 2010-08-26 Olink Ab Nucleic acid amplification method
EP2224016A1 (en) 2001-08-03 2010-09-01 Olink AB Method for generating a circularised nucleic acid
US7790388B2 (en) 2001-08-03 2010-09-07 Olink Ab Nucleic acid amplification method
EP2267117A2 (en) 2002-06-27 2010-12-29 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
EP2357194A1 (en) 2003-02-05 2011-08-17 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US9090706B2 (en) 2003-02-05 2015-07-28 Queensland University Of Technology Fibronectin: growth factor chimeras
EP2357195A1 (en) 2003-02-05 2011-08-17 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
WO2004099403A1 (en) 2003-05-12 2004-11-18 The University Of Queensland A method of increasing the total or soluble carbohydrate content or sweetness of an endogenous carbohydrate by catalysing the conversion of an endogenous sugar to an alien sugar.
EP2354231A1 (en) 2003-05-12 2011-08-10 The University Of Queensland A method of increasing the total or soluble carbohydrate content or sweetness of an endogenous carbohydrate by catalysing the conversion of an endogenous sugar to an alien sugar
EP2348116A2 (en) 2003-05-12 2011-07-27 The University Of Queensland A method of increasing the total or soluble carbohydrate content or sweetness of an endogenous carbohydrate by catalysing the conversion of an endogenous sugar to an alien sugar
EP2345729A2 (en) 2003-05-12 2011-07-20 The University Of Queensland A method of increasing the total or soluble carbohydrate content or sweetness of an endogenous carbohydrate by catalysing the conversion of an endogenous sugar to an alien sugar
WO2005108608A1 (en) * 2004-05-10 2005-11-17 Kabushiki Kaisha Dnaform Method for isolating nucleic acid isoforms
WO2006063415A1 (en) 2004-12-17 2006-06-22 Monash University Regulation of metalloprotease cleavage of cell surface proteins
JP2008526228A (en) * 2005-01-04 2008-07-24 日立化成工業株式会社 Primer-generated rolling circle amplification
EP1833994A2 (en) * 2005-01-04 2007-09-19 Hitachi Chemical Co., Ltd. Primer generation rolling circle amplification
EP2319940A1 (en) * 2005-01-04 2011-05-11 Hitachi Chemical Company, Ltd. Primer generation rolling circle amplification
EP1833994A4 (en) * 2005-01-04 2009-09-02 Hitachi Chemical Co Ltd Primer generation rolling circle amplification
US8916351B2 (en) 2005-01-04 2014-12-23 Hitachi Chemical Co., Ltd. Primer generation rolling circle amplification
WO2006095169A1 (en) * 2005-03-08 2006-09-14 Lingvitae As Method for preparing polynucleotides for analysis
EA012525B1 (en) * 2005-03-08 2009-10-30 Лингвитае Ас Method for preparing polynucleotides for analysis
US7989166B2 (en) 2005-04-12 2011-08-02 In Situ Rcp A/S Circle probes and their use in the identification of biomolecules
US8080393B2 (en) 2005-04-12 2011-12-20 Olink Ab Methods for production of oligonucleotides
US9944984B2 (en) 2005-06-15 2018-04-17 Complete Genomics, Inc. High density DNA array
US10351909B2 (en) 2005-06-15 2019-07-16 Complete Genomics, Inc. DNA sequencing from high density DNA arrays using asynchronous reactions
US20090011943A1 (en) * 2005-06-15 2009-01-08 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US9476054B2 (en) * 2005-06-15 2016-10-25 Complete Genomics, Inc. Two-adaptor library for high-throughput sequencing on DNA arrays
US11414702B2 (en) 2005-06-15 2022-08-16 Complete Genomics, Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
US9683255B2 (en) 2005-09-09 2017-06-20 Qiagen Gmbh Method for activating a nucleic acid for a polymerase reaction
US8093030B2 (en) 2005-10-06 2012-01-10 Lucigen Corporation Thermostable viral polymerases and methods of use
US7960104B2 (en) * 2005-10-07 2011-06-14 Callida Genomics, Inc. Self-assembled single molecule arrays and uses thereof
US20140073513A1 (en) * 2005-10-07 2014-03-13 Callida Genomics, Inc. Self-Assembled Single Molecule Arrays and Uses Thereof
US20090118488A1 (en) * 2006-02-24 2009-05-07 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US7501254B2 (en) 2006-07-20 2009-03-10 Ghc Technologies, Inc. Methods and compositions for amplification and capture of nucleic acid sequences
EP2058396A4 (en) * 2006-08-31 2010-06-30 Toyo Seikan Kaisha Ltd Nucleic acid amplification method
EP2058396A1 (en) * 2006-08-31 2009-05-13 Toyo Seikan Kaisha, Ltd. Nucleic acid amplification method
US7939299B2 (en) 2006-08-31 2011-05-10 Toyo Seikan Kaisha, Ltd. Nucleic acid amplification method
US9228228B2 (en) 2006-10-27 2016-01-05 Complete Genomics, Inc. Efficient arrays of amplified polynucleotides
WO2008144827A1 (en) 2007-05-31 2008-12-04 The University Of Queensland Diagnostic markers for ankylosing spondylitis and uses thereof
US11384388B2 (en) 2009-01-30 2022-07-12 Touchlight IP Limited DNA vaccines
US9109250B2 (en) 2009-01-30 2015-08-18 Vanessa Hill Production of closed linear DNA
WO2011063477A1 (en) 2009-11-30 2011-06-03 Queensland University Of Technology Fibronectin: growth factor chimeras
US9499847B2 (en) 2010-08-04 2016-11-22 Touchlight IP Limited Production of closed linear DNA using a palindromic sequence
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9701965B2 (en) 2010-10-01 2017-07-11 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US10174366B2 (en) 2012-11-14 2019-01-08 Olink Bioscience Ab Localised RCA-based amplification method
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US11649487B2 (en) 2013-03-15 2023-05-16 Labrador Diagnostics Llc Nucleic acid amplification
US10017809B2 (en) 2013-03-15 2018-07-10 Theranos Ip Company, Llc Nucleic acid amplification
US11603558B2 (en) 2013-03-15 2023-03-14 Labrador Diagnostics Llc Nucleic acid amplification
US9725760B2 (en) 2013-03-15 2017-08-08 Theranos, Inc. Nucleic acid amplification
US10131939B2 (en) 2013-03-15 2018-11-20 Theranos Ip Company, Llc Nucleic acid amplification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2970961A4 (en) * 2013-03-15 2016-12-21 Theranos Inc Nucleic acid amplification
US10745745B2 (en) 2013-03-15 2020-08-18 Labrador Diagnostics Llc Nucleic acid amplification
US9551027B2 (en) 2013-03-15 2017-01-24 Theranos, Inc. Nucleic acid amplification
US11254960B2 (en) 2013-03-15 2022-02-22 Labrador Diagnostics Llc Nucleic acid amplification
US10450595B2 (en) 2013-03-15 2019-10-22 Theranos Ip Company, Llc Nucleic acid amplification
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10522245B2 (en) 2013-09-06 2019-12-31 Theranos Ip Company, Llc Systems and methods for detecting infectious diseases
US10283217B2 (en) 2013-09-06 2019-05-07 Theranos Ip Company, Llc Systems and methods for detecting infectious diseases
US9916428B2 (en) 2013-09-06 2018-03-13 Theranos Ip Company, Llc Systems and methods for detecting infectious diseases
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10227632B2 (en) 2013-11-29 2019-03-12 Q-Linea Ab Rolling circle amplification method
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
US11918605B1 (en) 2015-02-19 2024-03-05 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US11649486B2 (en) 2016-08-16 2023-05-16 Navinci Diagnostics Ab Double-stranded circle probes
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US11739389B2 (en) 2017-05-17 2023-08-29 Microbio Pty Ltd Biomarkers and uses thereof
EP3424524A2 (en) 2017-07-04 2019-01-09 CureVac AG Cancer rna-vaccine
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
US11160822B2 (en) 2017-12-15 2021-11-02 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
US11458156B2 (en) 2017-12-15 2022-10-04 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
US10953033B2 (en) 2017-12-15 2021-03-23 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
US11058706B2 (en) 2017-12-15 2021-07-13 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
US11844759B2 (en) 2017-12-15 2023-12-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
WO2020180751A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Compositions, methods, and kits for delivery of polyribonucleotides
WO2020180752A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
WO2020181013A1 (en) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
WO2020198403A2 (en) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
WO2020257730A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
WO2020257727A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
WO2021155175A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
WO2021236980A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Coronavirus antigen compositions and their uses
WO2021236930A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2022066757A1 (en) 2020-09-23 2022-03-31 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells
US11944680B2 (en) 2020-11-04 2024-04-02 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023115013A1 (en) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides

Also Published As

Publication number Publication date
EP0542874A4 (en) 1994-05-11
EP0542874A1 (en) 1993-05-26
AU8417391A (en) 1992-02-18
CA2087256A1 (en) 1992-01-26
AU649066B2 (en) 1994-05-12
JPH06500014A (en) 1994-01-06

Similar Documents

Publication Publication Date Title
AU649066B2 (en) Circular extension for generating multiple nucleic acid complements
US5824517A (en) Method for amplifying nucleic acid sequences by strand displacement using DNA/RNA chimeric primers
EP0676476B1 (en) Isothermal strand displacement nucleic acid amplification
US5869251A (en) Use of primers containing nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules
CN107922970B (en) Target enrichment by single probe primer extension
US5554517A (en) Nucleic acid amplification process
US5215899A (en) Nucleic acid amplification employing ligatable hairpin probe and transcription
JP2703183B2 (en) Simultaneous amplification of multiple targets
JP3514630B2 (en) Amplification and detection of nucleic acid sequences
JP2807202B2 (en) Highly sensitive nucleic acid detection method
EP1184466A2 (en) Target nucleic acid enrichment and amplification for array analysis
EP1300466A2 (en) A cascade nucleic acid amplification reaction
JPH03180184A (en) Synthetic production of ribonucleic acid (dna)
US20200299764A1 (en) System and method for transposase-mediated amplicon sequencing
JPH08508636A (en) Amplification of nucleic acid sequences
JPH04229200A (en) Improved lcr process
WO2002059353A2 (en) Two-step amplification using a program primer followed by specific primers
KR20230124636A (en) Compositions and methods for highly sensitive detection of target sequences in multiplex reactions
WO2000020630A1 (en) Oligonucleotide primers that destabilize non-specific duplex formation and uses thereof
EP1573057A2 (en) Oligonucleotide guided analysis of gene expression
CN114364813B (en) Method for multiplex isothermal amplification of nucleic acid sequences
CA2332610A1 (en) Asymmetrical pcr applification
JP2002525076A (en) Method for isolating primer extension products using modular oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2087256

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991915255

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991915255

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991915255

Country of ref document: EP